Rituximab · Rituxan

Monoclonal antibody

Biosimilars tracked: PF-05280586, Rituximab-abbs (Truxima)

Approvedregulatory verdict

Evidence outlook

Approved: Rheumatoid Arthritis, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (4)
US
  • Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) RITUXAN, in combination with glucocorticoids, is indicated for the treatment of adult and pediatric patients 2 years of age and older with Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA).
    Outside this platform's coverage
  • Pemphigus Vulgaris (PV) RITUXAN is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris.Outside this platform's coverage
  • Adult patients with Non-Hodgkin's Lymphoma (NHL)
Product first approved 1997FDA label
EU
  • MabThera (rituximab) for rheumatoid arthritis, in combination with methotrexate, severe active RA after inadequate response to other DMARDs including TNF inhibitors
Product first approved 2006pharmafile.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (288)
Chronic Lymphocytic Leukemia
NCT03336333 · BeiGene
2017-10-31 – 2027-10-31 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04965493 · Loxo Oncology, Inc.
2021-09-20 – 2027-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01886872 · National Cancer Institute (NCI)
2014-01-15 – 2027-06-24 · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT02048813 · National Cancer Institute (NCI)
2014-03-10 – 2026-10-09 · Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01118234 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2009-12 – 2019-07 · Chronic Lymphocytic Leukemia
What this study did
NCT00769522 · German CLL Study Group
2008-10-02 – 2018-01 · Chronic Lymphocytic Leukemia
What this study did
NCT01973387 · Janssen Research & Development, LLC
2013-10-28 – 2017-08-11 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT00645606 · University Hospital, Tours
2007-12 – 2017-07 · Leukemia
What this study did
NCT00513747 · Alliance for Clinical Trials in Oncology
2008-01 – 2016-06 · Leukemia
What this study did
NCT00718549 · Hoffmann-La Roche
2009-07-21 – 2015-09-14 · Lymphocytic Leukemia, Chronic
What this study did
NCT00275054 · German CLL Study Group
2005-10 – 2015-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01670812 · The First Affiliated Hospital with Nanjing Medical University
2012-01 – 2014-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01539512 · Gilead Sciences
2012-04 – 2014-04 · Chronic Lymphocytic Leukemia
What this study did
NCT00254163 · US Oncology Research
2003-12 – 2011-09 · B-Cell Chronic Lymphocytic Leukemia
What this study did
Diffuse Large B-Cell Lymphoma
NCT07220187 · SWOG Cancer Research Network
2026-08-04 – 2036-10 · Richter Syndrome, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT06792253 · BeBetter Med Inc
2025-01-06 – 2029-06-30 · Relapsed/Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT06220032 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2024-08-15 – 2028-12-15 · DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT04384484 · ADC Therapeutics S.A.
2020-09-16 – 2028-06-30 · Relapsed Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT06929624 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
2025-04-24 – 2028-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT05351346 · Ruijin Hospital
2022-06-01 – 2026-06-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT05179733 · Ruijin Hospital
2022-03-02 – 2025-12-25 · Diffuse Large B-Cell Lymphoma
What this study did
NCT04833114 · GWT-TUD GmbH
2021-04-30 – 2025-12-19 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT04214444 · University Hospital, Tours
2020-07-03 – 2025-05-14 · Pneumococcal Infections, Lymphoma, Large B-Cell, Diffuse
What this study did
NCT02767674 · The First Affiliated Hospital with Nanjing Medical University
2016-05 – 2020-12 · Diffuse Large B Cell Lymphoma
What this study did
NCT02428751 · Wenqi Jiang
2015-09 – 2020-05 · Lymphoma, Large B-Cell, Diffuse
What this study did
NCT03372837 · SymBio Pharmaceuticals
2018-01-15 – 2019-12-31 · Assess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCL
What this study did
NCT01321541 · CTI BioPharma
2011-04-20 – 2018-09-14 · Diffuse Large B-cell Lymphoma, de Novo DLBCL, DLBCL Transformed From Indolent Lymphoma, Follicular Grade 3 Lymphoma
What this study did
NCT02617485 · Mabion SA
2015-12 – 2018-01 · Diffuse Large B-Cell Lymphoma
What this study did
NCT03151044 · FENG Ji-feng
2016-07 – 2017-07 · Diffuse Large B-cell Lymphoma
What this study did
NCT02268045 · mAbxience Research S.L.
2013-05 – 2017-07 · Diffuse Large B-cell Lymphoma
What this study did
NCT02366663 · City of Hope Medical Center
2015-01 – 2016-10 · Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT00499018 · Fondazione Italiana Linfomi - ETS
2006-01 – 2013-09 · Diffuse Large B-Cell Lymphoma, IPI≥2
What this study did
NCT00400478 · Arbeitsgemeinschaft medikamentoese Tumortherapie
2006-01 – 2013-03 · Diffuse Large B-Cell Lymphoma (DLBCL), Follicular NHL Grade 3b
What this study did
NCT00355199 · Gruppo Italiano Terapie Innovative nei Linfomi
2005-05 – 2013-03 · Diffuse Large B-Cell Lymphoma
What this study did
NCT00140660 · Lymphoma Study Association
2003-12 – 2012-04 · Diffuse Large Cell Lymphoma
What this study did
NCT00135499 · Lymphoma Study Association
2001-10-16 – 2010-04-27 · Lymphoma, Large-Cell, Diffuse
What this study did
Phase 2/3 (48)
Diffuse Large B-Cell Lymphoma
NCT03984448 · National Cancer Institute (NCI)
2019-10-22 – 2028-08-13 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Neoplastic Cells With Double Expression of MYC and BCL2 Proteins Present, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05139017 · Merck Sharp & Dohme LLC
2022-01-14 – 2027-09-24 · DLBCL, Diffuse Large B-Cell Lymphoma
What this study did
NCT04799275 · National Cancer Institute (NCI)
2021-05-20 – 2027-03-01 · Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Intravascular Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Nodular Lymphocyte Predominant B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT04442022 · Karyopharm Therapeutics Inc
2020-09-03 – 2026-12 · Relapsed/Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT02871869 · Xinjiang Medical University
2016-09 – 2021-12 · Diffuse, Large B-Cell, Lymphoma
What this study did
NCT01277172 · Probiomed S.A. de C.V.
2010-10 – 2011-10 · Diffuse Large B Cell Lymphoma
What this study did
Follicular Lymphoma
NCT07634471 · Merck Sharp & Dohme LLC
2026-06-22 – 2035-07-23 · Follicular Lymphoma
What this study did
NCT00096460 · Medical College of Wisconsin
2004-08 – 2009-03 · Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Follicular Lymphoma
What this study did
Other / comorbidity
NCT07724457 · National Cancer Institute (NCI)
2027-07-27 – 2033-11-01 · Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
What this study did
NCT05991388 · University of Birmingham
2024-05-02 – 2033-05-01 · B-cell Non Hodgkin Lymphoma
What this study did
NCT04061512 · University College, London
2020-02-03 – 2030-03 · Waldenstrom Macroglobulinemia
What this study did
NCT02405676 · Children's Cancer Group, China
2015-01-01 – 2029-12 · Mature B-cell Non-Hodgkin Lymphoma
What this study did
NCT07185373 · Huashan Hospital
2025-10-01 – 2029-07-30 · Primary Central Nervous System Lymphoma
What this study did
NCT03829566 · Northwestern University
2019-11 – 2025-11-28 · Neuromyelitis Optica, Devic's Disease, NMO Spectrum Disorder
What this study did
NCT03366272 · Universität des Saarlandes
2017-12-05 – 2025-01-15 · Lymphoma, Non-Hodgkin
What this study did
NCT05553496 · Ain Shams University
2022-09-25 – 2023-10-01 · Pharmacological Action
What this study did
NCT05963048 · Assiut University
2021-12-01 – 2023-06-01 · Interstitial Lung Disease, Scleroderma
What this study did
NCT03560011 · Assistance Publique - Hôpitaux de Paris
2019-04-03 – 2022-11-04 · Steroid-Dependent Nephrotic Syndrome
What this study did
NCT04074187 · Sanofi
2019-10-21 – 2021-05-19 · Thrombotic Thrombocytopenic Purpura
What this study did
NCT01862926 · Royal Brompton & Harefield NHS Foundation Trust
2014-11 – 2021-01 · Interstitial Lung Disease, Scleroderma, Idiopathic Inflammatory Myositis, Mixed Connective Tissue Disease
What this study did
NCT04274257 · Tokyo University
2017-12-04 – 2019-11-05 · Scleroderma, Systemic, Skin Sclerosis, Lung Fibrosis, Autoimmune Diseases, Collagen Diseases
What this study did
NCT03211065 · Rochester General Hospital
2017-07-21 – 2019-11-01 · Secondary Immune Deficiency
What this study did
NCT03593902 · Northwestern University
2018-05-17 – 2019-10-09 · Systemic Sclerosis, Scleroderma
What this study did
NCT03315923 · Isfahan University of Medical Sciences
2017-12-01 – 2019-03-01 · Secondary Progressive Multiple Sclerosis
What this study did
NCT02251964 · Human Adams
2014-09 – 2018-02 · Lung Diseases, Interstitial, Pneumonitis, Interstitial
What this study did
NCT01180036 · Mayo Clinic
2011-11 – 2017-10-01 · Idiopathic Membranous Nephropathy
What this study did
NCT03002038 · Isfahan University of Medical Sciences
2015-09 – 2016-12 · Neuromyelitis Optica Spectrum Disorder
What this study did
NCT01748084 · Assistance Publique - Hôpitaux de Paris
2013-04-09 – 2016-04-18 · Systemic Sclerosis
What this study did
NCT00565331 · Radboud University Medical Center
2007-12 – 2015-06 · Kidney Transplantation
What this study did
NCT00641095 · University College, London
2006-12-07 – 2015-05-22 · Lymphoma
What this study did
NCT01268033 · University Hospital, Limoges
2010-12 – 2014-05 · Childhood Idiopathic Nephrotic Syndrome
What this study did
NCT01716442 · Seoul National University Childrens Hospital
2012-08 – 2013-11 · Steroid Resistant Nephrotic Syndrome, Steroid Dependent Nephrotic Syndrome
What this study did
NCT00595335 · Rebecca Bahn
2008-04 – 2013-09 · Thyroid-associated Ophthalmopathy
What this study did
NCT00740948 · University Hospital, Brest
2008-03 – 2013-01 · Sjogren's Disease
What this study did
NCT00306670 · Georgetown University
2006-04 – 2011-08 · Hemophilia A
What this study did
NCT00749112 · Hospital Universitario Dr. Jose E. Gonzalez
2008-08 – 2010-08 · Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune
What this study did
NCT00848692 · Haukeland University Hospital
2008-06 – 2010-06 · Chronic Fatigue Syndrome
What this study did
NCT00147121 · Haruhiko Fukuda
2002-09 – 2010-02 · Lymphoma, B-Cell
What this study did
NCT00104299 · National Institute of Allergy and Infectious Diseases (NIAID)
2005-01 – 2010-01 · Vasculitis, Wegener's Granulomatosis, Microscopic Polyangiitis
What this study did
NCT00432653 · Charite University, Berlin, Germany
2007-03 – 2009-11 · Ankylosing Spondylitis
What this study did
NCT00261118 · Royal Liverpool University Hospital
2004-04 – 2009-10 · Ulcerative Colitis
What this study did
NCT00213512 · University Hospital, Rouen
2003-06 – 2008-10 · Pemphigus
What this study did
NCT00137969 · Genentech, Inc.
2005-05-10 – 2008-08-25 · Lupus Erythematosus, Systemic
What this study did
NCT00774202 · Weill Medical College of Cornell University
2003-11 – 2008-02 · Immune Thrombocytopenic Purpura
What this study did
NCT00087529 · Genentech, Inc.
2004-06 – 2007-10 · Multiple Sclerosis
What this study did
NCT00697996 · Stanford University
2005-06 – 2007-08 · Kidney Transplantation
What this study did
NCT00425217 · Mayo Clinic
2004-08 – 2007-04 · Membranous Nephropathy
What this study did
NCT00045877 · Chiron Corporation
— · Lymphoma, Non-Hodgkin
What this study did
Phase 2 (959)
Chronic Lymphocytic Leukemia
NCT06839053 · Fred Hutchinson Cancer Center
2025-06-02 – 2032-07-01 · Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT01446133 · M.D. Anderson Cancer Center
2011-12-12 – 2028-06-30 · Leukemia, Lymphoma
What this study did
NCT02007044 · M.D. Anderson Cancer Center
2013-12-06 – 2028-06-30 · Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
What this study did
NCT02339922 · University of Washington
2016-05-19 – 2028-01-08 · Chronic Lymphocytic Leukemia, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT04758975 · Paolo Ghia
2022-09-19 – 2027-12-30 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT04679012 · Weill Medical College of Cornell University
2021-09-24 – 2027-09 · Richter Syndrome, Chronic Lymphocytic Leukemia
What this study did
NCT04458610 · M.D. Anderson Cancer Center
2020-05-26 – 2027-05-26 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT02251548 · Dana-Farber Cancer Institute
2014-10 – 2027-01 · Chronic Lymphocytic Leukemia, Leukemia
What this study did
NCT03467867 · Georgetown University
2018-04-26 – 2026-12 · Chronic Lymphocytic Leukemia
What this study did
NCT03609593 · Nicole Lamanna
2018-11-12 – 2026-01-27 · Chronic Lymphocytic Leukemia
What this study did
NCT05287984 · Institute of Hematology & Blood Diseases Hospital, China
2022-03-22 – 2024-11-29 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed
What this study did
NCT02232386 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2015-03-02 – 2024-04-16 · Chronic Lymphocyte Leukemia, Adult Patients
What this study did
NCT03615105 · Memorial Sloan Kettering Cancer Center
2018-07-25 – 2024-03-06 · Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
What this study did
NCT03788291 · University of Rochester
2019-03-25 – 2023-05-19 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT03455517 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2018-10-31 – 2023-05-11 · Chronic Myeloid Leukemia
What this study did
NCT00602459 · National Cancer Institute (NCI)
2008-01-15 – 2023-04-15 · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT01027000 · Alliance for Clinical Trials in Oncology
2010-02 – 2023-04 · Leukemia, Lymphoma
What this study did
NCT03096782 · M.D. Anderson Cancer Center
2017-10-13 – 2022-09-20 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Minimal Residual Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Small Lymphocytic Lymphoma, Therapy-Related Myelodysplastic Syndrome
What this study did
NCT01199575 · University of California, San Diego
2010-08 – 2022-07-19 · Chronic Lymphocytic Leukemia, CLL
What this study did
NCT01723839 · Hackensack Meridian Health
2012-02-22 – 2021-06-08 · Chronic Lymphocytic Leukemia (CLL)
What this study did
NCT04155840 · University of Washington
2020-01-31 – 2021-03-16 · Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01125176 · Weill Medical College of Cornell University
2012-03-30 – 2020-12-29 · Chronic Lymphocytic Leukemia
What this study did
NCT00759798 · M.D. Anderson Cancer Center
2008-08-13 – 2020-07-22 · Chronic Lymphocytic Leukemia, Leukemia
What this study did
NCT02420938 · M.D. Anderson Cancer Center
2015-07 – 2020-07 · Leukemia
What this study did
NCT02481297 · M.D. Anderson Cancer Center
2015-06-23 – 2019-08-15 · Leukemia, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia
What this study did
NCT01576588 · Prof. Dr. Med. Laimonas Griskevicius
2011-10 – 2019-06 · B-Cell Chronic Lymphocytic Leukemia
What this study did
NCT01253460 · M.D. Anderson Cancer Center
2011-08-22 – 2019-02-13 · Leukemia
What this study did
NCT00899431 · M.D. Anderson Cancer Center
2009-05-06 – 2018-10-07 · Chronic Lymphocytic Leukemia
What this study did
NCT00711828 · Mayo Clinic
2008-08 – 2018-04-06 · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT00104858 · Fred Hutchinson Cancer Center
2004-12 – 2018-03-30 · Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma, T-Cell Large Granular Lymphocyte Leukemia
What this study did
NCT01044745 · University of Nebraska
2009-12-10 – 2017-10-10 · Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, de Novo Myelodysplastic Syndromes, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Graft Versus Host Disease, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenström Macroglobulinemia
What this study did
NCT00254410 · M.D. Anderson Cancer Center
2005-03-14 – 2017-09-14 · Chronic Lymphocytic Leukemia
What this study did
NCT01263704 · Hoffmann-La Roche
2011-07-17 – 2017-04-03 · Lymphocytic Leukemia, Chronic
What this study did
NCT01486797 · TME Pharma AG
2012-03 – 2017-04 · Chronic Lymphocytic Leukemia
What this study did
NCT00764517 · OHSU Knight Cancer Institute
2008-08 – 2017-03 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Indolent Adult Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma
What this study did
NCT00940342 · M.D. Anderson Cancer Center
2004-10-12 – 2017-01-05 · Leukemia
What this study did
NCT00425802 · Memorial Sloan Kettering Cancer Center
2006-11-28 – 2016-10-28 · Leukemia, Lymphoma
What this study did
NCT01181258 · Masonic Cancer Center, University of Minnesota
2010-08 – 2016-07 · Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
What this study did
NCT01203930 · Gilead Sciences
2010-10 – 2016-06 · Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
What this study did
NCT00545714 · Hoffmann-La Roche
2007-11-21 – 2016-05-20 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT02044822 · Gilead Sciences
2014-08-06 – 2016-05-17 · B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
What this study did
NCT00119392 · Fred Hutchinson Cancer Center
2004-06 – 2016-04-23 · B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT01370772 · French Innovative Leukemia Organisation
2011-05 – 2016-03 · B-cell Chronic Lymphocytic Leukemia CLL
What this study did
NCT00541034 · Memorial Sloan Kettering Cancer Center
2005-05 – 2016-01 · Leukemia, Lymphoma
What this study did
NCT01521689 · Institut Paoli-Calmettes
2011-12 – 2015-06 · Chronic Lymphocytic Leukemia
What this study did
NCT00096044 · Roswell Park Cancer Institute
2004-03 – 2015-06 · Leukemia
What this study did
NCT01625741 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2012-07 – 2015-05 · Chronic Lymphocytic Leukemia
What this study did
Phase 1/2 (239)
Chronic Lymphocytic Leukemia
NCT07520006 · Nurix Therapeutics, Inc.
2026-09-30 – 2033-05 · B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT06644183 · Jennifer R. Brown, MD, PhD
2025-03-19 – 2032-10-01 · Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia, Relapsed Cancer, Refractory Leukemia
What this study did
NCT06364423 · National Cancer Institute (NCI)
2024-09-03 – 2030-07-01 · Leukemia, Lymphocytic, Chronic, B-Cell, B-Lymphocytic Leukemia, Chronic, B-Cell Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Leukemia, Acute Lymphoblastic, Small Lymphocytic Lymphoma
What this study did
NCT04623541 · Genmab
2020-11-25 – 2028-02 · Relapsed/Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter's Syndrome, Treatment-naïve High Risk Chronic Lymphocytic Leukemia
What this study did
NCT02158091 · Dana-Farber Cancer Institute
2014-06-27 – 2026-12 · Chronic Lymphocytic Leukemia
What this study did
NCT03740529 · Loxo Oncology, Inc.
2019-03-15 – 2025-12-23 · Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Marginal Zone Lymphoma, B-cell Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT04494503 · Ascentage Pharma Group Inc.
2020-08-31 – 2025-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02213913 · University of Chicago
2014-07-29 – 2024-10-29 · Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage 0 Chronic Lymphocytic Leukemia, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
What this study did
NCT03492125 · MingSight Pharmaceuticals, Inc
2018-05-25 – 2023-11-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
What this study did
NCT02733042 · Celgene
2016-05-11 – 2022-08-21 · Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT04419389 · Aprea Therapeutics
2021-03-02 – 2021-08-24 · Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
What this study did
NCT02265731 · AbbVie
2014-09-22 – 2021-03-12 · Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Acute Myeloid Leukemia (AML)
What this study did
NCT01994382 · Alexion Pharmaceuticals, Inc.
2013-08-30 – 2020-12-15 · Follicular Lymphoma (FL/Indolent NHL), Aggressive NHL (a NHL), Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), T-cell Lymphoma (PTCL and CTCL), B-cell Non Hodgkin Lymphoma (NHL)
What this study did
NCT02315118 · National University Hospital, Singapore
2014-12 – 2018-12 · B-Cell Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
What this study did
NCT01096992 · M.D. Anderson Cancer Center
2010-04-19 – 2017-03-31 · Leukemia
What this study did
NCT00536341 · SCRI Development Innovations, LLC
2008-01 – 2016-11 · Chronic Lymphocytic Leukemia
What this study did
NCT00918723 · Fred Hutchinson Cancer Center
2009-06 – 2016-10 · Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
What this study did
NCT01558167 · German CLL Study Group
2011-02 – 2015-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01269385 · Mayo Clinic
2011-01 – 2015-06 · B-cell Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage 0 Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia
What this study did
NCT01326702 · National Cancer Institute (NCI)
2011-07 – 2015-04 · Adult B Acute Lymphoblastic Leukemia, Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult Solid Neoplasm, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Cutaneous B-Cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Hepatosplenic T-Cell Lymphoma, Intraocular Lymphoma, Lymphomatous Involvement of Non-Cutaneous Extranodal Site, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides and Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Plasma Cell Myeloma, Small Intestinal Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenstrom Macroglobulinemia
What this study did
NCT00546377 · Memorial Sloan Kettering Cancer Center
2005-07 – 2014-05 · Leukemia, Lymphoma
What this study did
NCT01369849 · National Cancer Institute (NCI)
2011-09 – 2014-02 · Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia
What this study did
NCT00288067 · National Cancer Institute (NCI)
2005-10 – 2013-07 · Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Stage II Marginal Zone Lymphoma, Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT00949988 · University of California, San Diego
2009-05 – 2012-04 · Chronic Lymphocytic Leukemia
What this study did
NCT00078234 · Genta Incorporated
2003-11 – 2010-09 · Chronic Lymphocytic Leukemia
What this study did
NCT00281983 · German CLL Study Group
2000-06 – 2010-07 · Chronic Lymphocytic Leukemia
What this study did
NCT00625729 · Masonic Cancer Center, University of Minnesota
2008-01 – 2010-04 · Leukemia, Lymphoma
What this study did
NCT00201682 · John Byrd
2002-10 – 2009-08 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
Diffuse Large B-Cell Lymphoma
NCT04231877 · University of Washington
2020-10-27 – 2031-12-01 · Aggressive Non-Hodgkin Lymphoma, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Gray-Zone Lymphoma
What this study did
NCT07124936 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
2025-07-30 – 2029-10-25 · Diffuse Large B Cell Lymphoma (DLBCL)
What this study did
NCT04856137 · National Health Research Institutes, Taiwan
2021-05-01 – 2028-12-31 · Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT07818499 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2028-12 · Diffuse Large B-Cell Lymphoma
What this study did
NCT07601607 · Sun Yat-sen University
2026-05-30 – 2028-11-30 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
What this study did
NCT07269639 · Seoul National University Hospital
2026-01-01 – 2028-09-01 · Large B-Cell Lymphoma (LBCL)
What this study did
NCT07159906 · First Affiliated Hospital of Zhejiang University
2025-09-08 – 2028-08-01 · Diffuse Large B-Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
What this study did
NCT05025800 · M.D. Anderson Cancer Center
2021-10-13 – 2028-03-21 · Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
What this study did
NCT04663347 · Genmab
2020-11-03 – 2027-09-30 · Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
What this study did
NCT04542824 · Genmab
2020-08-20 – 2027-09 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma
What this study did
NCT06594640 · Institute of Hematology & Blood Diseases Hospital, China
2024-05-30 – 2027-07-30 · Diffuse Large B-cell Lymphoma
What this study did
NCT00972478 · National Cancer Institute (NCI)
2010-11-15 – 2027-03-06 · Ann Arbor Stage II Non-Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma
What this study did
NCT05455697 · University of Washington
2023-01-26 – 2027-01-05 · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma
What this study did
NCT04058470 · Huiqiang Huang
2020-04-24 – 2025-12-30 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Grade IIIb, Transformed Lymphoma, EBV-Positive DLBCL, Nos, ALK-Positive Anaplastic Large Cell Lymphoma
What this study did
NCT02628405 · Academic and Community Cancer Research United
2016-05-20 – 2025-12-20 · Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
What this study did
NCT04607772 · Karyopharm Therapeutics Inc
2020-11-18 – 2025-12 · Relapsed or Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT04914741 · Peter MacCallum Cancer Centre, Australia
2021-06-29 – 2025-07 · Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma
What this study did
NCT03704714 · Northwestern University
2018-11-20 – 2025-06-11 · Aggressive Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, CD20 Positive, Diffuse Large B-Cell Lymphoma Unclassifiable, Intravascular Large B-Cell Lymphoma, Primary Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT05265975 · Antengene Corporation
2022-04-07 – 2024-12-31 · Diffuse Large B-cell Lymphoma, Indolent Non-Hodgkin Lymphoma
What this study did
NCT05267054 · BeiGene
2022-04-25 – 2024-08-30 · Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
What this study did
NCT02481310 · Northwestern University
2015-10-28 – 2024-07 · Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, MYC Gene Mutation, Plasmablastic Lymphoma
What this study did
Phase 1 (280)
Chronic Lymphocytic Leukemia
NCT05091424 · Hoffmann-La Roche
2022-03-07 – 2032-02-10 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT04843904 · Dana-Farber Cancer Institute
2021-04-14 – 2030-06-02 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02160015 · National Cancer Institute (NCI)
2014-05-20 – 2027-08-19 · Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma
What this study did
NCT02296918 · Acerta Pharma BV
2014-12-22 – 2025-10-22 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia
What this study did
NCT04981912 · University of California, San Diego
2021-09-02 – 2025-07-31 · Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
What this study did
NCT03524235 · Noah Merin
2018-07-18 – 2024-11-06 · Multiple Myeloma, CLL, Chronic Lymphocytic Leukemia, Lymphoma, Hodgkin Lymphoma
What this study did
NCT04245722 · Fate Therapeutics
2020-03-19 – 2023-09-27 · Lymphoma, B-Cell, Chronic Lymphocytic Leukemia
What this study did
NCT02960646 · M.D. Anderson Cancer Center
2017-01-18 – 2023-02-13 · Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Aplastic Anemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Therapy-Related Myelodysplastic Syndrome
What this study did
NCT01682616 · AbbVie
2012-07-25 – 2022-06-23 · Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia
What this study did
NCT01619761 · M.D. Anderson Cancer Center
2013-05-03 – 2021-11 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
What this study did
NCT03639324 · Virginia Commonwealth University
2020-10-02 – 2021-10-18 · Chronic Lymphocytic Leukemia, CLL, Relapsed CLL, Refractory Chronic Lymphocytic Leukemia, Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, SLL, Relapsed Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma
What this study did
NCT01644253 · Aptevo Therapeutics
2012-09 – 2021-04-21 · Chronic Lymphocytic Leukemia, Peripheral T-cell Lymphoma
What this study did
NCT01400685 · Massachusetts General Hospital
2012-12 – 2018-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, B Chronic Lymphocytic Leukemia
What this study did
NCT01292603 · Hoffmann-La Roche
2011-04-18 – 2017-11-17 · Lymphocytic Leukemia, Chronic
What this study did
NCT02200848 · Georgetown University
2014-04 – 2017-08-01 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02194374 · M.D. Anderson Cancer Center
2015-01 – 2017-06 · Leukemia
What this study did
NCT01832922 · Dartmouth-Hitchcock Medical Center
2013-04 – 2016-11-28 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01871675 · SCRI Development Innovations, LLC
2013-05 – 2016-06 · Lymphoma, Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, T-cell Lymphoma
What this study did
NCT01744626 · Celgene Corporation
2012-12 – 2015-12 · Leukemia Lymphocytic Chronic B-Cell
What this study did
NCT01373229 · David Rizzieri, MD
2012-01 – 2015-03 · Leukemia, Lymphocytic, Chronic, B-Cell
What this study did
NCT02168907 · Wake Forest University Health Sciences
2014-12 – 2015-02 · B-cell Adult Acute Lymphoblastic Leukemia, B-cell Chronic Lymphocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT00864942 · Georgetown University
2009-02 – 2014-10 · Chronic Lymphocytic Leukemia, Non-Hodgkin's Lymphoma
What this study did
NCT01410513 · Sanofi
2011-12 – 2014-05 · Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia
What this study did
NCT00330252 · Dana-Farber Cancer Institute
2006-05 – 2014-01 · Chronic Lymphocytic Leukemia
What this study did
NCT01650727 · Merck Sharp & Dohme LLC
2012-10 – 2013-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01185262 · MD Anderson International Spain SA
2009-04 – 2013-09 · Chronic Lymphocytic Leukemia
What this study did
NCT00612612 · National Cancer Institute (NCI)
2008-01 – 2013-07 · B-cell Chronic Lymphocytic Leukemia, Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage IV Chronic Lymphocytic Leukemia
What this study did
NCT00868413 · AbbVie (prior sponsor, Abbott)
2009-11 – 2013-05 · Chronic Lymphocytic Leukemia
What this study did
NCT00543114 · Dana-Farber Cancer Institute
2007-10 – 2012-12 · Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
What this study did
NCT01005979 · Emory University
2010-07 – 2012-10 · Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
What this study did
NCT01076556 · National Cancer Institute (NCI)
2010-04 – 2010-07 · Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage I Chronic Lymphocytic Leukemia, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Small Lymphocytic Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma
What this study did
NCT00366418 · National Heart, Lung, and Blood Institute (NHLBI)
2006-08-10 – 2009-06-11 · Refractory Chronic Lymphocytic Leukemia
What this study did
NCT00058227 · National Cancer Institute (NCI)
2003-04 – 2009-02 · B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Splenic Marginal Zone Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
What this study did
NCT00068315 · National Cancer Institute (NCI)
2003-07 – 2008-12 · Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
What this study did
NCT00098488 · National Cancer Institute (NCI)
2005-04 – 2008-04 · B-cell Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
What this study did
Diffuse Large B-Cell Lymphoma
NCT05934097 · Fate Therapeutics
2022-12 – 2039-05 · Diffuse Large B Cell Lymphoma, Transformed Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
What this study did
NCT07714421 · Jonsson Comprehensive Cancer Center
2026-12-08 – 2031-10-08 · Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma, High Grade B-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
NCT07649304 · National Cancer Institute (NCI)
2027-07-05 – 2028-12-01 · AIDS-Related Diffuse Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Lugano Classification Stage II Adult Non-Hodgkin Lymphoma AJCC v8, Lugano Classification Stage III Adult Non-Hodgkin Lymphoma AJCC v8, Lugano Classification Stage IV Adult Non-Hodgkin Lymphoma AJCC v8, Plasmablastic Lymphoma, Primary Effusion Lymphoma
What this study did
NCT04323956 · Mayo Clinic
2020-06-15 – 2028-05-16 · Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Indolent Non-Hodgkin Lymphoma
What this study did
NCT05052528 · University of California, Davis
2021-09-17 – 2027-12-15 · Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
What this study did
NCT07225439 · Paolo Caimi, MD
2026-09 – 2027-12 · Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
What this study did
NCT02337985 · City of Hope Medical Center
2015-11-20 – 2027-08-09 · AIDS-Related Burkitt Lymphoma, AIDS-Related Diffuse Large B-cell Lymphoma, AIDS-Related Plasmablastic Lymphoma, AIDS-Related Primary Effusion Lymphoma, HIV Infection, AIDS Related Non-Hodgkin Lymphoma
What this study did
NCT04609046 · National Cancer Institute (NCI)
2021-05-24 – 2027-08-01 · Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
What this study did
NCT03220022 · National Cancer Institute (NCI)
2018-03-16 – 2027-07-16 · AIDS-Related Lymphoma, Ann Arbor Stage II Diffuse Large B-Cell Lymphoma, Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
What this study did
NCT03321643 · National Cancer Institute (NCI)
2018-09-18 – 2027-06-30 · Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Richter Syndrome, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
What this study did
Phase 4 (85)
Chronic Lymphocytic Leukemia
NCT01271010 · Hoffmann-La Roche
2011-06-17 – 2016-05-04 · Lymphocytic Leukemia, Chronic
What this study did
NCT01056510 · Hoffmann-La Roche
2010-03 – 2014-03 · Lymphocytic Leukemia, Chronic
What this study did
NCT00131313 · East Valley Hematology and Oncology Medical Group
2003-01 – 2009-04 · Chronic Lymphocytic Leukemia
What this study did
Diffuse Large B-Cell Lymphoma
NCT07760610 · The First Hospital of Jilin University
2026-09 – 2029-07 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT02752815 · Ruijin Hospital
2016-06-14 – 2024-12-31 · Diffuse Large B-cell Lymphoma
What this study did
Follicular Lymphoma
NCT04842318 · Ruijin Hospital
2021-03-01 – 2024-03-01 · Follicular Lymphoma
What this study did
Rheumatoid Arthritis
NCT07643038 · Chinese SLE Treatment And Research Group
2026-09-20 – 2029-07-31 · Rheumatoid Arthritis Associated Interstitial Lung Disease
What this study did
NCT06003283 · Universitaire Ziekenhuizen KU Leuven
2024-01-09 – 2027-12 · Rheumatoid Arthritis
What this study did
NCT06906549 · University Hospital, Strasbourg, France
2025-07-11 – 2026-07 · Rheumatoid Arthritis (RA), Rituximab (RTx)
What this study did
NCT05116228 · Medical University of Vienna
2015-09-01 – 2021-11-01 · Rheumatoid Arthritis, Remission
What this study did
NCT01638715 · Medical University of Vienna
2012-05 – 2018-08-01 · Rheumatoid Arthritis
What this study did
NCT01021735 · University of Glasgow
2010-04 – 2015-04 · Rheumatoid Arthritis
What this study did
NCT01765374 · University Hospital, Rouen
2011-02 – 2014-10 · Rheumatoid Arthritis
What this study did
NCT01382940 · Hoffmann-La Roche
2011-07-26 – 2013-01-06 · Rheumatoid Arthritis
What this study did
NCT02731560 · Prof. Abid Z. Farooqi
2010-01 – 2012-12 · Rheumatoid Arthritis
What this study did
NCT01000610 · Hoffmann-La Roche
2008-03-17 – 2012-05-16 · Rheumatoid Arthritis
What this study did
NCT01593332 · Mashhad University of Medical Sciences
2010-07 – 2011-10 · DMARD Resistant Rheumatoid Arthritis
What this study did
NCT00934648 · Hoffmann-La Roche
2007-10 – 2010-11 · Rheumatoid Arthritis
What this study did
NCT00576433 · Hoffmann-La Roche
2007-12 – 2010-11 · Rheumatoid Arthritis
What this study did
NCT00502853 · Hoffmann-La Roche
2007-10-25 – 2010-07-23 · Rheumatoid Arthritis
What this study did
NCT01117129 · Hoffmann-La Roche
2010-04 – 2010-06 · Rheumatoid Arthritis
What this study did
NCT00424502 · Hoffmann-La Roche
2007-01 – 2009-10 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT05898308 · University Hospital, Rouen
2024-12-04 – 2032-05-01 · Pemphigus, Dermatologic Disease
What this study did
NCT04518475 · Institute of Hematology & Blood Diseases Hospital, China
2020-08-10 – 2030-08-10 · Primary Immune Thrombocytopenia (ITP)
What this study did
NCT06015750 · Alexion Pharmaceuticals, Inc.
2026-07-29 – 2030-03-13 · Hypophosphatasia
What this study did
NCT07451847 · Assistance Publique - Hôpitaux de Paris
2026-02 – 2030-02 · ANCA Associated Vasculitis (AAV), Polyangiitis (GPA), Microscopic Polyangiitis (MPA)
What this study did
NCT06134284 · Lixia Sheng
2023-01-02 – 2029-12-31 · OR Regimen for Relapsed/Refractory Marginal Zone Lymphoma
What this study did
NCT05207358 · Institutul Clinic Fundeni
2022-03-02 – 2028-12-31 · Lupus Nephritis
What this study did
NCT06031233 · Isala
2023-09-01 – 2028-12 · Oncology, Infusion Reaction
What this study did
NCT06611696 · Chiba University
2024-11-15 – 2028-09-30 · ANCA Associated Vasculitis (AAV)
What this study did
NCT07270835 · The First Affiliated Hospital of Soochow University
2025-11-01 – 2027-08 · Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
What this study did
NCT07788456 · Institute of Hematology & Blood Diseases Hospital, China
2026-06-22 – 2027-06-30 · ITP - Immune Thrombocytopenia
What this study did
NCT05514015 · First Affiliated Hospital, Sun Yat-Sen University
2024-03-29 – 2026-12-31 · Primary Membranous Nephropathy
What this study did
NCT06410833 · Peking Union Medical College Hospital
2024-03-09 – 2026-12-31 · Sjogren's Syndrome, Pediatric ALL
What this study did
NCT07051070 · Xuanwu Hospital, Beijing
2025-07-01 – 2026-11-01 · Anti-Vimentin Antibody-associated Diseases, Meningoencephalomyelitis Associated With Vimentin IgG Autoantibodies
What this study did
NCT05828147 · Chinese SLE Treatment And Research Group
2023-05-25 – 2026-03 · Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension
What this study did
NCT05494593 · Takeda
2023-02-28 – 2025-08-29 · Mucopolysaccharidosis (MPS), Hunter Syndrome
What this study did
NCT05861297 · Nahda University
2020-05-05 – 2024-04-02 · Immune Thrombocytopenia Purpura
What this study did
NCT04525729 · Nan Chen,MD
2020-07-01 – 2024-03-30 · IgA Nephropathy
What this study did
NCT02382575 · Nilratan Sircar Medical College
2015-03-15 – 2023-12 · Nephrotic Syndrome
What this study did
NCT05824390 · XIEJINGYUAN
2020-06-20 – 2023-10-01 · IgA Nephropathy
What this study did
NCT02844322 · Institute of Hematology & Blood Diseases Hospital, China
2016-05 – 2023-05 · Waldenström Macroglobulinemia
What this study did
NCT05191225 · Laida Cuevas Palomares
2021-09-28 – 2022-12 · Non-Hodgkin's Lymphoma
What this study did
NCT01095172 · Guy's and St Thomas' NHS Foundation Trust
2010-11 – 2022-10 · Function of Renal Transplant
What this study did
Early phase / not applicable (79)
Diffuse Large B-Cell Lymphoma
NCT07389356 · The First Affiliated Hospital with Nanjing Medical University
2026-02-25 – 2029-12-30 · DLBCL - Diffuse Large B Cell Lymphoma
What this study did
NCT07764601 · WEI XU
2026-08 – 2029-08 · Primary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma
What this study did
NCT07072208 · The First Affiliated Hospital of Soochow University
2024-11-01 – 2027-05-01 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01829958 · Memorial Sloan Kettering Cancer Center
2013-04 – 2027-04 · Non Hodgkin Lymphoma (NHL), Diffuse Large B-cell Lymphoma (DLBCL)
What this study did
NCT06832228 · Zhejiang Cancer Hospital
2024-09-01 – 2026-09-01 · Diffuse Large B-cell Lymphoma (DLBCL)
What this study did
NCT05990985 · The First Hospital of Jilin University
2023-09-01 – 2026-08-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT05809180 · The First Affiliated Hospital of Soochow University
2023-01-04 – 2026-07-03 · Diffuse Large B Cell Lymphoma
What this study did
NCT05784987 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-01-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT05777369 · The First Affiliated Hospital with Nanjing Medical University
2023-03 – 2024-08 · Diffuse Large B-cell Lymphoma
What this study did
NCT00544219 · Swiss Cancer Institute
2007-09 – 2016-01 · Lymphoma
What this study did
NCT00561379 · Nantes University Hospital
2005-04 – 2013-05 · Lymphoma, Large-Cell, Diffuse
What this study did
NCT00689845 · University Hospital Southampton NHS Foundation Trust
started 2007-06 · Lymphoma
What this study did
Follicular Lymphoma
NCT00772668 · University of Miami
2009-09-25 – 2011-02 · Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Rheumatoid Arthritis
NCT01643928 · Pfizer
2012-08-16 – 2016-03-14 · Rheumatoid Arthritis
What this study did
NCT00844714 · University of California, San Francisco
2009-11 – 2014-12 · Endothelial Function, Rheumatoid Arthritis, Inflammation
What this study did
NCT00963703 · University of Manitoba
2007-12 – 2012-03 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07299331 · Zhengzhou University
2026-01-01 – 2031-04-30 · Marginal Zone Lymphoma(MZL)
What this study did
NCT06190301 · Zhongshan Ophthalmic Center, Sun Yat-sen University
2023-12-20 – 2029-12-31 · Primary Ocular Adnexal MALT Lymphoma
What this study did
NCT07693881 · Nanfang Hospital, Southern Medical University
2026-07-01 – 2029-12-31 · EBV Infection After Allogenic HSCT
What this study did
NCT01599559 · International Extranodal Lymphoma Study Group (IELSG)
2012-10 – 2029-12-17 · Primary Mediastinal B-cell Lymphoma
What this study did
NCT06946407 · FengYan Jin
2022-12-02 – 2029-12-01 · Primary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma Treatment
What this study did
NCT07811557 · Centre Hospitalier Universitaire de Nice
2026-10-31 – 2029-10-31 · Membranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Nephrotic Syndrome
What this study did
NCT06942507 · Peking Union Medical College Hospital
2025-05-01 – 2029-04-30 · Waldenström's Macroglobulinemia (WM)
What this study did
NCT07675291 · Nanfang Hospital, Southern Medical University
2026-06 – 2028-12-31 · Lupus Nephritis
What this study did
NCT06832267 · Zhejiang Cancer Hospital
2025-02-14 – 2028-02-13 · Primary Central Nervous System Lymphoma
What this study did
NCT06980584 · Beijing Chao Yang Hospital
2025-02-10 – 2027-10-31 · Fibrosing Mediastinitis, Pulmonary Hypertension
What this study did
NCT06064344 · Zhongshan Ophthalmic Center, Sun Yat-sen University
2023-10-07 – 2027-10-06 · Primary Ocular Adnexal MALT Lymphoma
What this study did
NCT07071246 · Tang-Du Hospital
2022-08-01 – 2027-07-31 · Treatment
What this study did
NCT07206823 · The First Affiliated Hospital of Soochow University
2025-09-01 – 2027-07-31 · Primacy Immune Thrombocytopenia
What this study did
NCT07703657 · Yang Donglin
2026-07-09 – 2027-07-09 · Allogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemia
What this study did
NCT06478472 · The First Affiliated Hospital of Xiamen University
2024-06-23 – 2027-06-23 · Marginal Zone Lymphoma
What this study did
NCT07475754 · Peking Union Medical College Hospital
2026-03-23 – 2027-04-23 · Duchenne Muscular Dystrophy (DMD)
What this study did
NCT03500328 · Johns Hopkins University
2018-05-02 – 2026-08-31 · Multiple Sclerosis, Relapsing-Remitting
What this study did
NCT06245707 · Beijing Friendship Hospital
2023-10-01 – 2025-09-30 · Mild Cognitive Impairment, Idiopathic Membranous Nephropathy
What this study did
NCT01085617 · University College, London
2010-12 – 2025-02-24 · Leukemia, Mucositis, Oral Complications
What this study did
NCT05821192 · Ou Bai, MD/PHD
2023-03-23 – 2024-12-31 · Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma
What this study did
NCT05532111 · RenJi Hospital
2022-09-01 – 2024-09-30 · Efficacy and Safety
What this study did
NCT05679336 · St. Petersburg State Pavlov Medical University
2018-05-01 – 2024-08-31 · Membranous Nephropathy - PLA2R Induced
What this study did
NCT07049172 · Wuhan Children's Hospital
2021-01-01 – 2023-12-31 · Nephrotic Syndrome in Children
What this study did
NCT05782933 · Beijing Friendship Hospital
2022-08-04 – 2023-12-04 · Idiopathic Membranous Nephropathy
What this study did
NCT04319601 · Zhejiang Cancer Hospital
2020-03-13 – 2022-12-31 · Angioimmunoblastic T-cell Lymphoma, Chemotherapy Effect, Chemotherapeutic Toxicity
What this study did
NCT02652468 · University of Wisconsin, Madison
2016-03-10 – 2021-09-17 · Lymphoma
What this study did
NCT04610242 · Peking Union Medical College Hospital
2020-09-01 – 2020-12-31 · Drug Hypersensitivity Reaction
What this study did
NCT03507348 · University Hospital, Grenoble
2018-07-01 – 2019-11-21 · End-stage Renal Disease, Kidney Transplantation, Hla-incompatible Kidney Transplant Candidates
What this study did
NCT03584802 · Assistance Publique - Hôpitaux de Paris
2019-05-16 – 2019-11-15 · Exacerbation of Idiopathic Pulmonary Fibrosis
What this study did
NCT03154385 · Assistance Publique - Hôpitaux de Paris
2017-03-13 – 2019-11-13 · Immune Thrombocytopenia
What this study did
NCT01702961 · Baylor College of Medicine
2002-06 – 2017-01 · Lymphoma, Hodgkin's Disease
What this study did
NCT00594815 · Memorial Sloan Kettering Cancer Center
2002-08-28 – 2016-02-23 · Lymphoma
What this study did
NCT01719692 · Institute of Hematology & Blood Diseases Hospital, China
2012-10 – 2016-02 · Immune Thrombocytopenic Purpura
What this study did
NCT01598558 · Sanjiv Sam Gambhir
2012-01 – 2015-12 · Non-Hodgkin's Lymphoma
What this study did
Used as active comparator (130)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (76)
Chronic Lymphocytic Leukemia
NCT05947851 · Merck Sharp & Dohme LLC
2023-08-08 – 2035-07-01 · Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic, CLL, SLL
What this study did
NCT05624554 · Merck Sharp & Dohme LLC
2023-03-16 – 2031-03-17 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT07753369 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2026-08 – 2030-12 · Small Lymphocytic Lymppho, Relapsed/Refractory Chronic Lymphocytic Leukemia
What this study did
NCT07139873 · Dizal Pharmaceuticals
2025-09-08 – 2029-12 · Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
What this study did
NCT06970743 · BeOne Medicines
2025-05-29 – 2029-11-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT02970318 · Acerta Pharma BV
2017-02-02 – 2027-10-01 · Chronic Lymphocytic Leukemia
What this study did
NCT05023980 · Loxo Oncology, Inc.
2021-09-23 – 2027-10 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04666038 · Loxo Oncology, Inc.
2021-03-09 – 2027-05 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT04075292 · AstraZeneca
2020-01-20 – 2027-01-01 · Untreated Chronic Lymphocytic Leukemia
What this study did
NCT04578613 · Beijing InnoCare Pharma Tech Co., Ltd.
2021-01-08 – 2025-06-30 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01998880 · Hoffmann-La Roche
2009-12-22 – 2017-08-23 · Lymphocytic Leukemia, Chronic
What this study did
NCT01010061 · Hoffmann-La Roche
2009-12-21 – 2017-08-23 · Lymphocytic Leukemia, Chronic
What this study did
NCT02053610 · Hoffmann-La Roche
2009-12-31 – 2017-08-23 · Lymphocytic Leukemia, Chronic
What this study did
Diffuse Large B-Cell Lymphoma
NCT07808827 · Shanghai Junshi Bioscience Co., Ltd.
2026-10-08 – 2030-02-28 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05040906 · Shandong New Time Pharmaceutical Co., LTD
2020-10-13 – 2023-12-31 · Recruiting
What this study did
NCT04361279 · Shanghai Institute Of Biological Products
2019-07-25 – 2022-05-20 · Diffuse Large B-Cell Lymphoma
What this study did
NCT03777085 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2019-01-10 – 2020-12-30 · Diffuse Large B-cell Lymphoma
What this study did
NCT02867566 · Innovent Biologics (Suzhou) Co. Ltd.
2016-08-22 – 2019-12-26 · Diffuse, Large B-Cell, Lymphoma
What this study did
NCT03670901 · JHL Biotech, Inc.
2018-11-13 – 2019-03-07 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01287741 · Hoffmann-La Roche
2011-07-26 – 2018-01-31 · Diffuse Large B-Cell Lymphoma
What this study did
NCT01659099 · The Lymphoma Academic Research Organisation
2012-09 – 2017-12-31 · Diffuse Large B Cell Lymphoma CD20 Positive
What this study did
NCT01014208 · GlaxoSmithKline
2010-03 – 2014-11 · Lymphoma, Large-Cell, Diffuse
What this study did
Follicular Lymphoma
NCT07736950 · Australasian Leukaemia and Lymphoma Group
2027-01-12 – 2035-01-13 · Follicular Lymphoma
What this study did
NCT06284122 · The Lymphoma Academic Research Organisation
2024-06-07 – 2034-04 · Follicular Lymphoma
What this study did
NCT06313996 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
2024-03-29 – 2031-10-16 · Relapsed or Refractory Follicular Lymphoma
What this study did
NCT06149286 · Regeneron Pharmaceuticals
2023-12-28 – 2031-04-30 · Relapsed/Refractory Follicular Lymphoma, Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
What this study did
NCT05888493 · Novartis Pharmaceuticals
2023-10-02 – 2031-02-20 · Follicular Lymphoma (FL)
What this study did
NCT05371093 · Kite, A Gilead Company
2022-09-22 – 2030-10 · Relapsed/Refractory Follicular Lymphoma
What this study did
NCT07562022 · Sinocelltech Ltd.
2026-06-09 – 2029-06 · Follicular Lymphoma (FL)
What this study did
NCT07187960 · Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
2025-11 – 2029-02 · Follicular Lymphoma
What this study did
NCT01303887 · University of Liverpool
2009-10 – 2023-05-11 · Follicular Lymphoma
What this study did
NCT04671420 · Shanghai Henlius Biotech
2020-10 – 2022-10 · CD20-positive Follicular Lymphoma, With Low Tumour Burden
What this study did
NCT02260804 · Celltrion
2015-11-09 – 2019-09-04 · Follicular Lymphoma
What this study did
NCT01419665 · Sandoz
2011-12-01 – 2018-01-22 · Follicular Lymphoma
What this study did
NCT02417129 · Boehringer Ingelheim
2015-04 – 2015-12 · Lymphoma, Non-Hodgkin
What this study did
NCT00991211 · University of Giessen
2004-01 – 2009-08 · Non-Hodgkin Lymphomas, Follicular Lymphomas, Immunocytomas, Lymphocytic Lymphomas, Marginal Zone Lymphomas
What this study did
Rheumatoid Arthritis
NCT04680962 · Mabion SA
2023-08-03 – 2023-08-03 · Rheumatoid Arthritis
What this study did
NCT04268771 · Dr. Reddy's Laboratories Limited
2020-04-08 – 2022-04-20 · Rheumatoid Arthritis
What this study did
NCT02792699 · Amgen
2016-05-17 – 2018-10-08 · Arthritis, Rheumatoid
What this study did
Phase 2/3 (5)
Diffuse Large B-Cell Lymphoma
NCT07917754 · Merck Sharp & Dohme LLC
2026-12-13 – 2037-03-13 · Lymphoma, Large B-Cell, Diffuse, Diffuse Large B-Cell Lymphoma
What this study did
NCT01197560 · Celgene
2010-09-02 – 2018-04-05 · Diffuse Large B-cell Lymphoma
What this study did
Other / comorbidity
NCT05786768 · Assistance Publique - Hôpitaux de Paris
2023-10-18 – 2027-06-30 · Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome
What this study did
NCT05063513 · European Society for Blood and Marrow Transplantation
2009-07 – 2017-07 · REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS
What this study did
Phase 2 (28)
Chronic Lymphocytic Leukemia
NCT01466153 · MedImmune LLC
2012-02-07 – 2016-01-08 · Chronic Lymphocytic Leukemia (CLL)
What this study did
Diffuse Large B-Cell Lymphoma
NCT07189065 · Guangzhou Lupeng Pharmaceutical Company LTD.
2025-11-27 – 2028-12-31 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
NCT03485118 · Zhejiang Hisun Pharmaceutical Co. Ltd.
2016-05-12 – 2018-01-14 · Diffuse Large B-cell Lymphoma
What this study did
NCT01453205 · MedImmune LLC
2012-02-27 – 2016-07-11 · Diffuse Large B-Cell Lymphoma
What this study did
Follicular Lymphoma
NCT05848765 · University of Birmingham
2023-09-04 – 2031-11-30 · Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
What this study did
NCT00850499 · Millennium Pharmaceuticals, Inc.
2009-09 – 2011-10 · Follicular Lymphoma
What this study did
Rheumatoid Arthritis
Other / comorbidity
NCT06655896 · Novartis Pharmaceuticals
2024-10-29 – 2032-08-30 · Scleroderma, Diffuse
What this study did
NCT07208981 · The First Affiliated Hospital with Nanjing Medical University
2025-08-14 – 2031-06-01 · Marginal Zone Lymphoma(MZL)
What this study did
NCT07917780 · German CLL Study Group
2026-06-18 – 2030-05-15 · Richter Transformation
What this study did
NCT05886036 · National Cancer Institute (NCI)
2024-01-23 – 2028-10-31 · Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
What this study did
NCT07362238 · Institute of Hematology & Blood Diseases Hospital, China
2026-03 – 2028-03 · Immune Thrombocytopenia, Treatment
What this study did
NCT07297563 · Institute of Hematology & Blood Diseases Hospital, China
2026-01-20 – 2027-11 · Immune Thrombocytopenia, Treatment
What this study did
NCT06561360 · Memorial Sloan Kettering Cancer Center
2024-09-09 – 2027-09-09 · Hairy Cell Leukemia
What this study did
NCT04920968 · Maria Sklodowska-Curie National Research Institute of Oncology
2021-10-05 – 2026-04-21 · CD20-positive Acute Lymphoblastic Leukemia
What this study did
NCT05376319 · Mayo Clinic
2023-06-30 – 2024-05-07 · Granulomatosis With Polyangiitis, Microscopic Polyangiitis, ANCA Associated Vasculitis
What this study did
NCT04154787 · Novartis Pharmaceuticals
2019-11-23 – 2023-01-20 · Idiopathic Membranous Nephropathy
What this study did
NCT02631538 · GlaxoSmithKline
2016-02-17 – 2020-06-23 · Sjogren's Syndrome
What this study did
NCT02394119 · Istituto Giannina Gaslini
2015-06 – 2019-05 · Nephrotic Syndrome
What this study did
NCT02624492 · Boehringer Ingelheim
2016-01-28 – 2018-03-16 · Lymphoma, Large B-Cell, Diffuse
What this study did
NCT01047072 · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
est. completion 2017-09 · Systemic Scleroderma
What this study did
NCT01889797 · PrECOG, LLC.
2013-12 – 2016-08 · Indolent Non-Hodgkin's Lymphoma
What this study did
NCT02456207 · Sinocelltech Ltd.
2015-05 – 2015-12 · B-cell Non Hodgkin's Lymphoma
What this study did
NCT00238238 · Alliance for Clinical Trials in Oncology
2006-03 – 2015-08 · Lymphoma
What this study did
NCT00576758 · Hoffmann-La Roche
2008-01 – 2013-03 · Non-Hodgkin's Lymphoma
What this study did
NCT00230035 · National Institute of Allergy and Infectious Diseases (NIAID)
started 2005-09 · Systemic Lupus Erythematosus
What this study did
NCT00311129 · Genzyme, a Sanofi Company
2005-12 – 2007-07 · Lymphoma, Low-Grade
What this study did
Phase 1/2 (7)
Rheumatoid Arthritis
NCT06475495 · Charite University, Berlin, Germany
2024-12-04 – 2027-06 · Rheumatoid Arthritis
What this study did
NCT02296775 · Dr. Reddy's Laboratories Limited
2014-11 – 2017-10-05 · Rheumatoid Arthritis
What this study did
NCT01274182 · Sandoz
2011-01 – 2016-11 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03456466 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
2017-05-01 – 2018-06-30 · Non-hodgkin's Lymphoma
What this study did
NCT02584920 · Shanghai Henlius Biotech
2014-10 – 2015-08 · B-cell Non Hodgkin's Lymphoma
What this study did
NCT00400764 · Genentech, Inc.
2006-06 – 2010-05 · Non-Hodgkin's Lymphoma
What this study did
Phase 1 (11)
Follicular Lymphoma
NCT01950273 · Boehringer Ingelheim
2013-09-27 – 2015-12-22 · Lymphoma, Follicular
What this study did
Rheumatoid Arthritis
NCT03161457 · JHL Biotech, Inc.
2017-02-27 – 2019-04-16 · Rheumatoid Arthritis, Arthritis, Rheumatoid
What this study did
NCT02819726 · Archigen Biotech Limited
2016-10-11 – 2018-11-07 · Rheumatoid Arthritis
What this study did
NCT03061838 · Biointegrator LLC
2016-10-27 – 2018-03-14 · Rheumatoid Arthritis
What this study did
NCT02371096 · Gedeon Richter Plc.
est. completion 2016-06 · Rheumatoid Arthritis
What this study did
NCT01123070 · Teva Pharmaceutical Industries, Ltd.
2010-02-05 – 2012-04-23 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03980379 · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
2018-12-18 – 2019-10-31 · CD20 Positive B Cell NHL
What this study did
NCT03003039 · Nanjing Yoko Biomedical Co., Ltd.
2017-06-05 – 2019-05-20 · B-Cell Lymphoma
What this study did
NCT03670888 · JHL Biotech, Inc.
2018-11-16 – 2019-03-19 · B Cell Lymphoma
What this study did
NCT01205737 · Teva Branded Pharmaceutical Products R&D, Inc.
2010-09 – 2013-09 · DLBCL
What this study did
Phase 4 (3)
Rheumatoid Arthritis
NCT01295151 · Julia Brown
2011-08 – 2015-11 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07010302 · Massachusetts General Hospital
2026-09-01 – 2030-05 · NMOSD
What this study did
NCT04127747 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2020-08-18 – 2023-07-01 · Autoimmune Diseases
What this study did
Studied as part of a combination product (10)

Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.

Phase 3 (1)
Follicular Lymphoma
NCT05100862 · BeOne Medicines
2022-03-10 – 2030-06 · Relapsed/Refractory Follicular Lymphoma, Marginal Zone Lymphoma
What this study did
Phase 2 (7)
Diffuse Large B-Cell Lymphoma
NCT06176729 · Yan Zhang, MD
2023-10-24 – 2027-10-24 · Diffuse Large B Cell Lymphoma
What this study did
NCT06921044 · Xiaohui He
2025-04-16 – 2027-03-01 · Diffuse Large B-Cell Lymphoma
What this study did
NCT06086197 · Zhejiang Cancer Hospital
2023-10-01 – 2026-10 · Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
What this study did
NCT04460248 · Ruijin Hospital
2020-08-26 – 2025-12-01 · Diffuse Large B Cell Lymphoma
What this study did
Other / comorbidity
NCT07022223 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-03-11 – 2029-09-11 · Marginal Zone Lymphoma(MZL)
What this study did
NCT07029737 · AstraZeneca
2025-09-05 – 2029-06-30 · Mantle-cell Lymphoma
What this study did
NCT06263491 · M.D. Anderson Cancer Center
2024-05-29 – 2028-11-01 · Mantle Cell Lymphoma
What this study did
Phase 1/2 (1)
Diffuse Large B-Cell Lymphoma
Early phase / not applicable (1)
Other / comorbidity
NCT05482542 · Scripps Health
2023-01-01 – 2027-07-01 · Multiple Sclerosis, Relapsing-Remitting
What this study did
Appears in other studies (62)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (33)
Chronic Lymphocytic Leukemia
NCT01569295 · Gilead Sciences
2012-06-15 – 2019-06-10 · Chronic Lymphocytic Leukemia
What this study did
NCT01611090 · Janssen Research & Development, LLC
2012-09-19 – 2019-01-23 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
What this study did
NCT01980888 · Gilead Sciences
2014-02-05 – 2016-06-16 · Chronic Lymphocytic Leukemia
What this study did
Diffuse Large B-Cell Lymphoma
NCT06522555 · Ruijin Hospital
2024-07-29 – 2029-08-10 · Diffuse Large B-Cell Lymphoma
What this study did
NCT05018520 · Ruijin Hospital
2021-09-17 – 2028-06-30 · Diffuse Large B Cell Lymphoma
What this study did
NCT04824092 · Incyte Corporation
2021-05-11 – 2027-11-01 · Diffuse Large B-cell Lymphoma
What this study did
NCT04529772 · Acerta Pharma BV
2020-10-08 – 2027-02-22 · Diffuse Large B-Cell Lymphoma
What this study did
NCT04404283 · Seagen, a wholly owned subsidiary of Pfizer
2020-08-20 – 2026-12-31 · Diffuse Large B-cell Lymphoma
What this study did
NCT04231448 · Chipscreen Biosciences, Ltd.
2020-05-21 – 2025-06-29 · Diffuse Large B-cell Lymphoma
What this study did
NCT02285062 · Celgene
2015-02-17 – 2022-07-28 · Lymphoma, Large B-Cell, Diffuse
What this study did
NCT02128061 · The Lymphoma Academic Research Organisation
2014-08 – 2021-01 · Diffuse Large B Cell Lymphoma
What this study did
Follicular Lymphoma
NCT04796922 · Incyte Corporation
2022-12-30 – 2032-08-25 · Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
What this study did
NCT02320292 · Mayo Clinic
2015-02-11 – 2023-11-09 · Ann Arbor Stage I Grade 1 Follicular Lymphoma, Ann Arbor Stage I Grade 2 Follicular Lymphoma, Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma, Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma
What this study did
NCT01938001 · Celgene
2013-11-21 – 2022-01-26 · Lymphoma, Non-Hodgkin
What this study did
NCT02204982 · SecuraBio
2014-09 – 2017-03 · Follicular Lymphoma
What this study did
NCT02576275 · SecuraBio
2015-12 – 2016-11 · Indolent Non-Hodgkin's Lymphoma, Follicular Lymphoma, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma
What this study did
NCT01662102 · Spectrum Pharmaceuticals, Inc
2012-12-11 – 2013-03-05 · Follicular Lymphoma
What this study did
Other / comorbidity
NCT05735834 · International Extranodal Lymphoma Study Group (IELSG)
2024-05-21 – 2029-05 · Splenic Marginal Zone Lymphoma
What this study did
NCT02972840 · Acerta Pharma BV
2017-04-05 – 2027-02-15 · Lymphoma, Mantle Cell
What this study did
NCT04743739 · Peking Union Medical College Hospital
2021-04-14 – 2024-12-20 · Idiopathic Membranous Nephropathy
What this study did
NCT01776840 · Janssen Research & Development, LLC
2013-05-16 – 2024-06-24 · Mantle Cell Lymphoma
What this study did
NCT02626455 · Bayer
2016-01-06 – 2023-11-10 · Lymphoma, Non-Hodgkin
What this study did
NCT04531865 · Children's Hospital of Fudan University
2021-01-01 – 2022-10-01 · Frequently Relapsing Nephrotic Syndrome, Steroid-Dependent Nephrotic Syndrome
What this study did
NCT03443570 · Shandong University
2018-03-01 – 2021-03-01 · Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
What this study did
NCT00841945 · French Innovative Leukemia Organisation
2005-04 – 2017-02 · B Cell Lymphoma
What this study did
Phase 2/3 (2)
Diffuse Large B-Cell Lymphoma
NCT07712588 · Dizal Pharmaceuticals
2026-09 – 2032-02 · Diffuse Large B-Cell Lymphoma (DLBCL)
What this study did
Other / comorbidity
NCT07861204 · Peking University First Hospital
2026-01-21 – 2027-12-30 · Membranous Nephropathy
What this study did
Phase 2 (20)
Chronic Lymphocytic Leukemia
Diffuse Large B-Cell Lymphoma
The CARDIOPROTECT Trialnot yet recruiting
NCT07654426 · Beth Israel Deaconess Medical Center
2026-12-01 – 2035-12-31 · Diffuse Large B-cell Lymphoma (DLBCL), Cardiotoxicity, Lymphoma
What this study did
NCT05280626 · Innovent Biologics (Suzhou) Co. Ltd.
2022-03-25 – 2026-12-31 · Diffuse Large B-Cell Lymphoma
What this study did
NCT04113226 · Centre Hospitalier Universitaire, Amiens
2021-11-09 – 2024-06-04 · Chemotherapy, Diffuse Large B-Cell Lymphoma (DLBCL), Nos, Elderly
What this study did
NCT00945724 · International Extranodal Lymphoma Study Group (IELSG)
2009-09-27 – 2023-09-26 · Large B-cell Diffuse Lymphoma of Testis
What this study did
NCT03188198 · Mansoura University
2016-06-01 – 2019-06-01 · Large B Cell Lymphoma
What this study did
Rheumatoid Arthritis
NCT00664521 · Merck KGaA, Darmstadt, Germany
2008-03 – 2010-10 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT03949855 · National Institute of Allergy and Infectious Diseases (NIAID)
2020-03-06 – 2030-03-01 · Membranous Nephropathy, Nephrotic Syndrome
What this study did
NCT06047171 · Alentis Therapeutics AG
2023-09-07 – 2028-02-28 · Glomerulonephritis Rapidly Progressive
What this study did
NCT07057778 · Peking University People's Hospital
2025-07-01 – 2027-07-01 · Immune Thrombocytopenia (ITP)
What this study did
NCT07081022 · Shanghai Junshi Bioscience Co., Ltd.
2025-08-17 – 2027-04-06 · B-cell Non-Hodgkin's Lymphoma
What this study did
NCT06388941 · Novartis Pharmaceuticals
2024-08-05 – 2026-12-30 · Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
What this study did
NCT05186558 · The First Affiliated Hospital with Nanjing Medical University
2022-05-15 – 2026-02-15 · Lymphoma, Large B-Cell, Diffuse, Neoplasms by Histologic Type
What this study did
NCT04842487 · Sun Yat-sen University
2021-04-10 – 2023-12-30 · DLBCL
What this study did
NCT04021992 · Sun Yat-sen University
2019-07-15 – 2023-12-15 · Lymphoma, Large B-Cell, Diffuse
What this study did
NCT01399372 · Radiation Therapy Oncology Group
2011-09 – 2022-05-20 · Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Lymphoma, Neurotoxicity, Radiation Toxicity
What this study did
NCT00193492 · SCRI Development Innovations, LLC
2005-09 – 2013-03 · Lymphoma, Follicular
What this study did
NCT00646750 · Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
2008-01 – 2012-06 · Non-Hodgkin's Lymphoma
What this study did
NCT00529503 · Seagen Inc.
2007-09 – 2011-05 · Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
What this study did
NCT00367497 · Keio University
2005-08 – 2007-11 · Lymphoma, Non-Hodgkin
What this study did
Phase 1/2 (3)
Other / comorbidity
NCT02843061 · Fuda Cancer Hospital, Guangzhou
2016-07-01 – 2019-07-01 · B-cell Lymphoma Recurrent
What this study did
NCT02563340 · First Affiliated Hospital, Sun Yat-Sen University
2015-11 – 2017-11 · Kidney Transplantation
What this study did
NCT00299182 · M.D. Anderson Cancer Center
2006-03 – 2012-04 · Lymphoma
What this study did
Phase 1 (1)
Other / comorbidity
NCT01831505 · Presage Biosciences
2012-11 – 2013-07 · Lymphoma
What this study did
Phase 4 (2)
Rheumatoid Arthritis
NCT01000441 · University Hospital, Strasbourg, France
2009-12-23 – 2013-08-12 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT04083066 · Mingzhi Zhang
2019-09-05 – 2024-04-01 · Primary Central Nervous System Lymphoma
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT04519710 · Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
2020-09-15 – 2023-10-15 · HBV
What this study did

Competitive landscape

This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Chronic Lymphocytic Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Rituximab (Rituxan): this drugApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic Antibodynot yet gradedNo reviewed efficacy summary in this indication
AcalabrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
AlemtuzumabApprovedMonoclonal antibodyCD52not yet gradedNo reviewed efficacy summary in this indication
IbrutinibApprovedSmall moleculeBTKPartial signal
NCT01611090: Progression-free Survival (PFS) (Up to 5 years): Ibrutinib+BR 65.12 Months | Placebo+BR 14.32 Months (95% CI 13.86 to 16.62)
ObinutuzumabApprovedMonoclonal antibodyCD20Partial signalNo reviewed efficacy summary in this indication
Ocrelizumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
Ocrevus Zunovo
Approved(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Ofatumumab
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20not yet gradedNo reviewed efficacy summary in this indication
PirtobrutinibApprovedSmall moleculeBTKPartial signalFeatured results are non-efficacy only in this race
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Ublituximab (Briumvi)
Approved(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
VenetoclaxApprovedSmall moleculeBCL-2Partial signal
NCT02005471: Investigator-assessed PFS, venetoclax-rituximab vs bendamustine-rituximab: 2-year rates 84.9% vs 36.3% (hazard ratio 0.17; P<0.001)
Zanubrutinib (Brukinsa)ApprovedSmall moleculeBTKPartial signal
NCT03734016: Overall response rate, zanubrutinib (n=327) vs ibrutinib (n=325): by independent review 86.2% vs 75.7%, response ratio 1.14 (95% CI 1.05 to 1.22), non-inferiority p<0.0001, superiority p=0.0007; by investigator 83.5% vs 74.2%, response ratio 1.12 (95% CI 1.04 to 1.22), non-inferiority p<0.0001, superiority p=0.0035 (CT.gov posted results).
ABP 692
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BCD-281
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
BexobrutidegPhase 3Small moleculeBruton's tyrosine kinase (BTK)not yet gradedNo reviewed efficacy summary in this indication
CT-P53
Phase 3(overall)
Monoclonal antibodyCD20
not yet graded(overall)
No reviewed efficacy summary in this indication
Divozilimab (Ivlizi)
Phase 3(overall)
Monoclonal antibodyCD20
Reliable signal(overall)
No reviewed efficacy summary in this indication
NemtabrutinibPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Sonrotoclax (Beqalzi)Phase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 2/3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MS-553Phase 1/2Small moleculeProtein kinase C-beta (PKC-beta)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(321 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Rituxan (Rituximab) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (23)
November 2026 (1)
Phase 1LymphomaActive not recruiting
Est. primary completion 2026-11 · NCT03352765 · CT.gov ↗
What to watch
December 2026 (22)
Phase 1/2Crohn's DiseaseRecruiting
Est. primary completion 2026-12 · NCT00692939 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2026-12 · NCT03467867 · CT.gov ↗
What to watch
Phase 2/3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2026-12 · NCT04442022 · CT.gov ↗
What to watch
Phase 1Follicular LymphomaActive not recruiting
Est. primary completion 2026-12-01 · NCT01479842 · CT.gov ↗
What to watch
Phase 2IgM MGUS, Waldenstrom Macroglobulinemia, Neuropathy;PeripheralActive not recruiting
Est. primary completion 2026-12-01 · NCT05065554 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2026-12-01 · NCT03758989 · CT.gov ↗
What to watch
Phase 2Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2026-12-01 · NCT06561347 · CT.gov ↗
What to watch
Phase 1/2Primary Central Nervous System Lymphoma, Recurrent Cancer, Refractory Cancer, Relapsed CancerRecruiting
Est. primary completion 2026-12-05 · NCT04421560 · CT.gov ↗
What to watch
Phase 1Lymphoma, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06475235 · CT.gov ↗
What to watch
Phase 2Severe Aplastic Anemia, Platelet Transfusion RefractorinessRecruiting
Est. primary completion 2026-12-30 · NCT06254560 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2026-12-30 · NCT06471738 · CT.gov ↗
What to watch
Phase 1Follicular LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06209619 · CT.gov ↗
What to watch
Phase 1Follicular LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03361852 · CT.gov ↗
What to watch
Phase 1Refractory Systemic Lupus Erythematosus, Refractory Lupus NephritisRecruiting
Est. primary completion 2026-12-31 · NCT06676631 · CT.gov ↗
What to watch
Phase 1Lymphoma, B-CellActive not recruiting
Est. primary completion 2026-12-31 · NCT04161248 · CT.gov ↗
What to watch
Phase 2Relapsed/Refractory Large B-Cell LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06489808 · CT.gov ↗
What to watch
Phase 2High Titers of Anti-HLA Antibody (MFI ≥5000)Recruiting
Est. primary completion 2026-12-31 · NCT06362967 · CT.gov ↗
What to watch
Phase 2Liver Lymphoma, Mantle Cell LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT04115631 · CT.gov ↗
What to watch
Phase 2Blastic Plasmacytoid Dendritic Cell NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04216524 · CT.gov ↗
What to watch
Phase 2Mucosa-associated Lymphoid Tissue Lymphoma (MALT)Active not recruiting
Est. primary completion 2026-12-31 · NCT06647732 · CT.gov ↗
What to watch
Phase 2LymphomaActive not recruiting
Est. primary completion 2026-12-31 · NCT02436707 · CT.gov ↗
What to watch
Phase 4OR Regimen for Relapsed/Refractory Marginal Zone LymphomaRecruiting
Est. primary completion 2026-12-31 · NCT06134284 · CT.gov ↗
What to watch
2027 (128)
January 2027 (9)
Phase 2MCL, Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-01 · NCT05214183 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-01 · NCT04679012 · CT.gov ↗
What to watch
Phase 3Polymyalgia RheumaticaActive not recruiting
Est. primary completion 2027-01 · NCT05533164 · CT.gov ↗
What to watch
Phase 2Fanconi Anemia, Severe Aplastic Anemia, Myelodysplastic Syndromes, T Cell Receptor Alpha/Beta Depletion, Telomere Biology Disorder …Recruiting
Est. primary completion 2027-01-01 · NCT03579875 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-01-08 · NCT06572618 · CT.gov ↗
What to watch
Phase 1/2Malignant TumorsRecruiting
Est. primary completion 2027-01-11 · NCT05615974 · CT.gov ↗
What to watch
Phase 3Lymphoma, Large B-Cell, DiffuseNot yet recruiting
Est. primary completion 2027-01-12 · NCT06573645 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-01-16 · NCT04978584 · CT.gov ↗
What to watch
Phase 3Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-01-31 · NCT03267433 · CT.gov ↗
What to watch
February 2027 (6)
Phase 2Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-02 · NCT05583071 · CT.gov ↗
What to watch
Phase 2Sickle Cell Disease, Thalassemia, Beta, ThalassemiaRecruiting
Est. primary completion 2027-02-09 · NCT05736419 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System LymphomaRecruiting
Est. primary completion 2027-02-13 · NCT06832267 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia With BCR-ABL1 …Active not recruiting
Est. primary completion 2027-02-28 · NCT03147612 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-02-28 · NCT06522386 · CT.gov ↗
What to watch
Early phase / not applicablePrimacy Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-02-28 · NCT07206823 · CT.gov ↗
What to watch
March 2027 (12)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2027-03 · NCT07362199 · CT.gov ↗
What to watch
Phase 2Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03 · NCT05249959 · CT.gov ↗
What to watch
Phase 2Relapsed or Refractory Large B-cell LymphomaRecruiting
Est. primary completion 2027-03 · NCT06788964 · CT.gov ↗
What to watch
Phase 3Severe Forms of Mucous Membrane PemphigoidActive not recruiting
Est. primary completion 2027-03 · NCT03295383 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-03 · NCT06929624 · CT.gov ↗
What to watch
Phase 2/3Follicular LymphomaActive not recruiting
Est. primary completion 2027-03-01 · NCT04799275 · CT.gov ↗
What to watch
Phase 2Double Expressor DLBCL, ELDERLY PEOPLE, Unfit, New-diagnosis DLBCLRecruiting
Est. primary completion 2027-03-11 · NCT07884708 · CT.gov ↗
What to watch
Phase 3Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-03-18 · NCT04212013 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-22 · NCT03710772 · CT.gov ↗
What to watch
Phase 1Lymphoma, Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05495464 · CT.gov ↗
What to watch
Phase 2Type 1 Diabetes MellitusActive not recruiting
Est. primary completion 2027-03-31 · NCT03929601 · CT.gov ↗
What to watch
Phase 4ANCA Associated Vasculitis (AAV)Recruiting
Est. primary completion 2027-03-31 · NCT06611696 · CT.gov ↗
What to watch
April 2027 (10)
Phase 3Acute Demyelinating Syndrome, Myelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseRecruiting
Est. primary completion 2027-04 · NCT05545384 · CT.gov ↗
What to watch
Phase 4Hemophagocytic Lymphohistiocytosis, B Cell LymphomaRecruiting
Est. primary completion 2027-04 · NCT07270835 · CT.gov ↗
What to watch
Early phase / not applicableDiffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-04 · NCT01829958 · CT.gov ↗
What to watch
Phase 2Primary Membranous NephropathyNot yet recruiting
Est. primary completion 2027-04-01 · NCT07029139 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaActive not recruiting
Est. primary completion 2027-04-01 · NCT05303792 · CT.gov ↗
What to watch
Phase 1/2Lymphoma, Non-HodgkinActive not recruiting
Est. primary completion 2027-04-07 · NCT03930953 · CT.gov ↗
What to watch
Phase 2Lymphoma, Lymphoma, B-CellRecruiting
Est. primary completion 2027-04-14 · NCT06954805 · CT.gov ↗
What to watch
Phase 3ANCA Associated Vasculitis (AAV)Recruiting
Est. primary completion 2027-04-16 · NCT07168161 · CT.gov ↗
What to watch
Phase 2Psychosis, Autoimmune EncephalitisActive not recruiting
Est. primary completion 2027-04-30 · NCT03194815 · CT.gov ↗
What to watch
Early phase / not applicableWaldenström's Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2027-04-30 · NCT06942507 · CT.gov ↗
What to watch
May 2027 (9)
Phase 1Myeloid DiseasesActive not recruiting
Est. primary completion 2027-05 · NCT03531736 · CT.gov ↗
What to watch
Phase 3Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS …Recruiting
Est. primary completion 2027-05 · NCT05834855 · CT.gov ↗
What to watch
Early phase / not applicableDiffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-05-01 · NCT07072208 · CT.gov ↗
What to watch
Phase 1Pemphigus Vulgaris, Rituximab (RTx)Not yet recruiting
Est. primary completion 2027-05-05 · NCT07769333 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-05-20 · NCT01473628 · CT.gov ↗
What to watch
Phase 2Mantle-cell LymphomaRecruiting
Est. primary completion 2027-05-24 · NCT05868395 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-05-26 · NCT04458610 · CT.gov ↗
What to watch
Phase 4ITP - Immune ThrombocytopeniaRecruiting
Est. primary completion 2027-05-30 · NCT07788456 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia …Recruiting
Est. primary completion 2027-05-31 · NCT02727803 · CT.gov ↗
What to watch
June 2027 (14)
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT04416451 · CT.gov ↗
What to watch
Phase 3Mature B-cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT03206671 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-06 · NCT05578976 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-06-10 · NCT06834373 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-06-15 · NCT03697512 · CT.gov ↗
What to watch
Early phase / not applicableMarginal Zone LymphomaRecruiting
Est. primary completion 2027-06-23 · NCT06478472 · CT.gov ↗
What to watch
Phase 1/2Mantle Cell LymphomaRecruiting
Est. primary completion 2027-06-24 · NCT03523975 · CT.gov ↗
What to watch
Phase 1Mature B-cell MalignanciesRecruiting
Est. primary completion 2027-06-25 · NCT06351527 · CT.gov ↗
What to watch
Phase 1B-cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT06251180 · CT.gov ↗
What to watch
Phase 1Follicular LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT03321643 · CT.gov ↗
What to watch
Phase 2Hairy Cell Leukemia, Recurrent Hairy Cell LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT00412594 · CT.gov ↗
What to watch
Phase 2Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT02427620 · CT.gov ↗
What to watch
Phase 3Primary Mediastinal Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-06-30 · NCT04759586 · CT.gov ↗
What to watch
Early phase / not applicableTreatmentActive not recruiting
Est. primary completion 2027-06-30 · NCT07071246 · CT.gov ↗
What to watch
July 2027 (8)
Phase 1Rheumatoid ArthritisRecruiting
Est. primary completion 2027-07 · NCT06581562 · CT.gov ↗
What to watch
Phase 1PTLD, Epstein Barr Virus (EBV) Infection, Solid Organ TransplantNot yet recruiting
Est. primary completion 2027-07 · NCT07614282 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2027-07-08 · NCT06504940 · CT.gov ↗
What to watch
Early phase / not applicableAllogeneic Hematopoietic Stem Cell Transplantation, Epstein-Barr Virus Reactivation, Clinically Significant EBV DNAemiaNot yet recruiting
Est. primary completion 2027-07-09 · NCT07703657 · CT.gov ↗
What to watch
Phase 3Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2027-07-10 · NCT06496308 · CT.gov ↗
What to watch
Phase 1Relapsed/Refractory B-cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-07-30 · NCT07073833 · CT.gov ↗
What to watch
Phase 1/2Hematopoietic and Lymphoid System NeoplasmRecruiting
Est. primary completion 2027-07-31 · NCT04022239 · CT.gov ↗
What to watch
Phase 2DLBCL, Lymphoma, B-CellActive not recruiting
Est. primary completion 2027-07-31 · NCT04594798 · CT.gov ↗
What to watch
August 2027 (9)
Phase 1Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus, SLEActive not recruiting
Est. primary completion 2027-08 · NCT06265220 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-08-01 · NCT04609046 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-08-01 · NCT07159906 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-08-01 · NCT04998669 · CT.gov ↗
What to watch
Phase 2Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma …Recruiting
Est. primary completion 2027-08-01 · NCT03136146 · CT.gov ↗
What to watch
Phase 2Ann Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Lymphoma …Recruiting
Est. primary completion 2027-08-03 · NCT04745949 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-08-09 · NCT02337985 · CT.gov ↗
What to watch
Phase 1Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2027-08-10 · NCT07697339 · CT.gov ↗
What to watch
Phase 2Systemic SclerosisActive not recruiting
Est. primary completion 2027-08-30 · NCT03844061 · CT.gov ↗
What to watch
September 2027 (8)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09 · NCT04542824 · CT.gov ↗
What to watch
Phase 1Ann Arbor Stage II Mantle Cell Lymphoma, Ann Arbor Stage III Mantle Cell Lymphoma, Ann Arbor Stage IV Mantle Cell LymphomaNot yet recruiting
Est. primary completion 2027-09-01 · NCT07444710 · CT.gov ↗
What to watch
Phase 2/3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-09-24 · NCT05139017 · CT.gov ↗
What to watch
Phase 2Lymphoma, Indolent Non-hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-09-29 · NCT06557330 · CT.gov ↗
What to watch
Phase 1/2Indolent B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-09-30 · NCT03571568 · CT.gov ↗
What to watch
Phase 1/2Large B-cell LymphomaNot yet recruiting
Est. primary completion 2027-09-30 · NCT07638787 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT04663347 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2027-09-30 · NCT05683171 · CT.gov ↗
What to watch
October 2027 (11)
Phase 1/2B-Cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2027-10 · NCT05201248 · CT.gov ↗
What to watch
Phase 3CIDPRecruiting
Est. primary completion 2027-10 · NCT06714838 · CT.gov ↗
What to watch
Phase 3Large B-Cell LymphomaActive not recruiting
Est. primary completion 2027-10-01 · NCT06047080 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Ocular Adnexal MALT LymphomaNot yet recruiting
Est. primary completion 2027-10-06 · NCT06064344 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-10-12 · NCT04002947 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-10-26 · NCT07124936 · CT.gov ↗
What to watch
Phase 1/2Relapsed/Refractory Non-Hodgkin LymphomaRecruiting
Est. primary completion 2027-10-28 · NCT06090539 · CT.gov ↗
What to watch
Phase 2Primary Intraocular LymphomaRecruiting
Est. primary completion 2027-10-30 · NCT06973811 · CT.gov ↗
What to watch
Early phase / not applicableDiffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-10-30 · NCT07389356 · CT.gov ↗
What to watch
Phase 2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia …Active not recruiting
Est. primary completion 2027-10-31 · NCT01424982 · CT.gov ↗
What to watch
Early phase / not applicableFibrosing Mediastinitis, Pulmonary HypertensionRecruiting
Est. primary completion 2027-10-31 · NCT06980584 · CT.gov ↗
What to watch
November 2027 (6)
Phase 1Central Nervous System LymphomaActive not recruiting
Est. primary completion 2027-11 · NCT03684980 · CT.gov ↗
What to watch
Phase 2ST Elevated Myocardial InfarctionRecruiting
Est. primary completion 2027-11 · NCT05211401 · CT.gov ↗
What to watch
Phase 2Lymphoma, Mantle-CellRecruiting
Est. primary completion 2027-11-01 · NCT06136351 · CT.gov ↗
What to watch
Phase 3B Acute Lymphoblastic LeukemiaRecruiting
Est. primary completion 2027-11-01 · NCT03150693 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-11-15 · NCT07001540 · CT.gov ↗
What to watch
Phase 2Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53 …Recruiting
Est. primary completion 2027-11-30 · NCT05735717 · CT.gov ↗
What to watch
December 2027 (26)
Phase 1Follicular LymphomaRecruiting
Est. primary completion 2027-12 · NCT07225439 · CT.gov ↗
What to watch
Phase 1/2Idiopathic Pulmonary Fibrosis, Emphysema or COPDRecruiting
Est. primary completion 2027-12 · NCT03500731 · CT.gov ↗
What to watch
Phase 1/2Fanconi AnemiaRecruiting
Est. primary completion 2027-12 · NCT04784052 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2027-12 · NCT04623541 · CT.gov ↗
What to watch
Phase 2Relapsed B-Cell Non-Hodgkin LymphomaNot yet recruiting
Est. primary completion 2027-12 · NCT07477366 · CT.gov ↗
What to watch
Phase 2T-cell LymphomaActive not recruiting
Est. primary completion 2027-12 · NCT06756308 · CT.gov ↗
What to watch
Phase 3Anti-MAG NeuropathyRecruiting
Est. primary completion 2027-12 · NCT05136976 · CT.gov ↗
What to watch
Phase 3Idiopathic Membranous NephropathyRecruiting
Est. primary completion 2027-12 · NCT04745728 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2027-12 · NCT06003283 · CT.gov ↗
What to watch
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-01 · NCT07269639 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Central Nervous System Lymphoma (PCNSL), CNS Lymphoma TreatmentRecruiting
Est. primary completion 2027-12-01 · NCT06946407 · CT.gov ↗
What to watch
Phase 1B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Mixed Phenotype Acute Leukemia …Active not recruiting
Est. primary completion 2027-12-02 · NCT04872790 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-12-13 · NCT06890884 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-20 · NCT07034508 · CT.gov ↗
What to watch
Phase 1/2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative …Recruiting
Est. primary completion 2027-12-25 · NCT01371630 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2027-12-30 · NCT06742502 · CT.gov ↗
What to watch
Phase 2Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2027-12-30 · NCT07405255 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaActive not recruiting
Est. primary completion 2027-12-30 · NCT03474744 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT06441097 · CT.gov ↗
What to watch
Phase 2Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2027-12-31 · NCT07041268 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma of Ocular Adnexal, Marginal Zone Lymphoma(MZL)Active not recruiting
Est. primary completion 2027-12-31 · NCT07247383 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2027-12-31 · NCT07418190 · CT.gov ↗
What to watch
Phase 2Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative DisorderRecruiting
Est. primary completion 2027-12-31 · NCT05786040 · CT.gov ↗
What to watch
Phase 2Newly Diagnosed MYC/BCL2 Double-expressor DLBCLActive not recruiting
Est. primary completion 2027-12-31 · NCT07538180 · CT.gov ↗
What to watch
Phase 2LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT05645718 · CT.gov ↗
What to watch
Phase 2Nephrotic Syndrome, Proteinuria, Autoimmune Disease, Glomerular Disease, Membranous GlomerulonephritisRecruiting
Est. primary completion 2027-12-31 · NCT00977977 · CT.gov ↗
What to watch
2028 (84)
January 2028 (6)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06765317 · CT.gov ↗
What to watch
Phase 2Marginal Zone Lymphoma(MZL)Recruiting
Est. primary completion 2028-01-01 · NCT07448324 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaActive not recruiting
Est. primary completion 2028-01-01 · NCT05788081 · CT.gov ↗
What to watch
Phase 2LymphomaRecruiting
Est. primary completion 2028-01-09 · NCT07015242 · CT.gov ↗
What to watch
Phase 3Thrombocytopenia PurpuraNot yet recruiting
Est. primary completion 2028-01-31 · NCT07051915 · CT.gov ↗
What to watch
February 2028 (2)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-02 · NCT05783609 · CT.gov ↗
What to watch
Phase 3Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA)Recruiting
Est. primary completion 2028-02 · NCT06983821 · CT.gov ↗
What to watch
March 2028 (7)
Phase 2Waldenstrom Macroglobulinemia, Treatment NaiveRecruiting
Est. primary completion 2028-03 · NCT05099471 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-03 · NCT06508658 · CT.gov ↗
What to watch
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-03-01 · NCT04404088 · CT.gov ↗
What to watch
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2028-03-21 · NCT05025800 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaNot yet recruiting
Est. primary completion 2028-03-30 · NCT07550855 · CT.gov ↗
What to watch
Phase 2Lymphoplasmacytic Lymphoma, Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2028-03-31 · NCT04840602 · CT.gov ↗
What to watch
April 2028 (6)
Phase 1/2Double Expressor DLBCLNot yet recruiting
Est. primary completion 2028-04-01 · NCT07415980 · CT.gov ↗
What to watch
Phase 2Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder, Brief Psychotic Disorder …Enrolling by invitation
Est. primary completion 2028-04-01 · NCT04323566 · CT.gov ↗
What to watch
Phase 2Waldenstrom Macroglobulinemia, Lymphoplasmacytic LymphomaRecruiting
Est. primary completion 2028-04-11 · NCT07231952 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2028-04-24 · NCT06911502 · CT.gov ↗
What to watch
Phase 1Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-04-28 · NCT06541665 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-04-30 · NCT06803693 · CT.gov ↗
What to watch
May 2028 (3)
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-05-30 · NCT07601607 · CT.gov ↗
What to watch
Phase 2Non-hodgkin LymphomaRecruiting
Est. primary completion 2028-05-31 · NCT05998642 · CT.gov ↗
What to watch
Phase 2Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)Recruiting
Est. primary completion 2028-05-31 · NCT06952413 · CT.gov ↗
What to watch
June 2028 (9)
Phase 3Ocular Myasthenia GravisRecruiting
Est. primary completion 2028-06 · NCT06342544 · CT.gov ↗
What to watch
Phase 3Primary Central Nervous System LymphomaActive not recruiting
Est. primary completion 2028-06 · NCT04931368 · CT.gov ↗
What to watch
Phase 1Diffuse Large Cell Lymphoma, Non-Hodgkin Lymphoma, Burkitt Lymphoma, Plasmablastic Lymphoma, B-Cell NeoplasmRecruiting
Est. primary completion 2028-06-01 · NCT05389423 · CT.gov ↗
What to watch
Phase 1/2Combination Therapy, Aggressive B-Cell Non-Hodgkin Lymphoma, EMB07, phaseI/IIRecruiting
Est. primary completion 2028-06-30 · NCT07432022 · CT.gov ↗
What to watch
Phase 2Waldenström Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2028-06-30 · NCT07259122 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-06-30 · NCT01446133 · CT.gov ↗
What to watch
Phase 2Richter SyndromeActive not recruiting
Est. primary completion 2028-06-30 · NCT03899337 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaActive not recruiting
Est. primary completion 2028-06-30 · NCT02007044 · CT.gov ↗
What to watch
Phase 3Glomerulonephritis, Membranous, Nephrotic Syndrome,IdiopathicActive not recruiting
Est. primary completion 2028-06-30 · NCT05914155 · CT.gov ↗
What to watch
July 2028 (11)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2028-07 · NCT05058404 · CT.gov ↗
What to watch
Phase 4Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-07 · NCT07760610 · CT.gov ↗
What to watch
Phase 4Oncology, Infusion ReactionRecruiting
Est. primary completion 2028-07 · NCT06031233 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2028-07-01 · NCT07199296 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2028-07-01 · NCT06905509 · CT.gov ↗
What to watch
Phase 3Interstitial Lung Disease With Systemic SclerosisRecruiting
Est. primary completion 2028-07-08 · NCT06549231 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-07-30 · NCT07397832 · CT.gov ↗
What to watch
Phase 1Glioma of Spinal Cord, Glioma of BrainstemRecruiting
Est. primary completion 2028-07-31 · NCT04196413 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 …Recruiting
Est. primary completion 2028-07-31 · NCT07224100 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-07-31 · NCT06045247 · CT.gov ↗
What to watch
Phase 2CCND1 Positive, CCND2 Positive, CCND3 Positive, CD20 Positive, Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma …Active not recruiting
Est. primary completion 2028-07-31 · NCT01880567 · CT.gov ↗
What to watch
August 2028 (10)
Early phase / not applicableDiffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08 · NCT07764601 · CT.gov ↗
What to watch
Phase 1Immune-Related Adverse EventsRecruiting
Est. primary completion 2028-08-01 · NCT07694414 · CT.gov ↗
What to watch
Phase 1/2Sickle Cell Anemia, Beta-thalassemia Major, Diamond-blackfan AnemiaRecruiting
Est. primary completion 2028-08-01 · NCT03653338 · CT.gov ↗
What to watch
Phase 2Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary HypertensionRecruiting
Est. primary completion 2028-08-01 · NCT03630211 · CT.gov ↗
What to watch
Phase 2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-08-01 · NCT06839053 · CT.gov ↗
What to watch
Phase 2/3Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2028-08-13 · NCT03984448 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaActive not recruiting
Est. primary completion 2028-08-30 · NCT04765111 · CT.gov ↗
What to watch
Phase 1Lymphoma, Non-HodgkinRecruiting
Est. primary completion 2028-08-31 · NCT07308132 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-08-31 · NCT07588698 · CT.gov ↗
What to watch
Phase 3Relapsed/Refractory Marginal Zone LymphomaRecruiting
Est. primary completion 2028-08-31 · NCT06082102 · CT.gov ↗
What to watch
September 2028 (5)
Phase 1Follicular LymphomaRecruiting
Est. primary completion 2028-09 · NCT07226843 · CT.gov ↗
What to watch
Phase 1Waldenström Macroglobulinemia (WM)Not yet recruiting
Est. primary completion 2028-09-01 · NCT07169565 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2028-09-10 · NCT07272499 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-09-30 · NCT07255963 · CT.gov ↗
What to watch
Phase 2/3Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-09-30 · NCT07185373 · CT.gov ↗
What to watch
October 2028 (6)
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2028-10 · NCT05635162 · CT.gov ↗
What to watch
Phase 2Lymphoma, Marginal Zone Lymphoma, MZLRecruiting
Est. primary completion 2028-10 · NCT06510309 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2028-10-01 · NCT06644183 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-10-01 · NCT06516978 · CT.gov ↗
What to watch
Phase 2Lymphoproliferative Disorder, HHV-8, Malignancy, HIVActive not recruiting
Est. primary completion 2028-10-01 · NCT00092222 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL)Active not recruiting
Est. primary completion 2028-10-31 · NCT05951959 · CT.gov ↗
What to watch
November 2028 (5)
Phase 2Immune Thrombocytopenia, TreatmentRecruiting
Est. primary completion 2028-11 · NCT07234019 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, B Lymphoblastic LymphomaRecruiting
Est. primary completion 2028-11-01 · NCT02877303 · CT.gov ↗
What to watch
Phase 2Primary CNS LymphomaRecruiting
Est. primary completion 2028-11-02 · NCT04627753 · CT.gov ↗
What to watch
Phase 3Systemic SclerosisNot yet recruiting
Est. primary completion 2028-11-14 · NCT07335562 · CT.gov ↗
What to watch
Phase 2Phase 2 Study, MCL, BTKi, Rituximab, GlofitamabRecruiting
Est. primary completion 2028-11-24 · NCT07257055 · CT.gov ↗
What to watch
December 2028 (14)
Phase 1/2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-12 · NCT07818499 · CT.gov ↗
What to watch
Phase 1Lymphoma, B-CellActive not recruiting
Est. primary completion 2028-12-01 · NCT04884035 · CT.gov ↗
What to watch
Phase 1Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-12-01 · NCT07649304 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2028-12-01 · NCT07938619 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma (MCL), Relapsed/Refractory Mantle Cell Lymphoma (MCL)Not yet recruiting
Est. primary completion 2028-12-08 · NCT07944651 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-12-15 · NCT06220032 · CT.gov ↗
What to watch
Phase 2LymphomasRecruiting
Est. primary completion 2028-12-30 · NCT07002099 · CT.gov ↗
What to watch
Phase 2Primary Central Nervous System Lymphoma (PCNSL), Secondary Central Nervous System Lymphoma (SCNSL)Recruiting
Est. primary completion 2028-12-31 · NCT07410520 · CT.gov ↗
What to watch
Phase 2PCNSL, Primary Central Nervous System LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT07350850 · CT.gov ↗
What to watch
Phase 2KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8Recruiting
Est. primary completion 2028-12-31 · NCT01419561 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2028-12-31 · NCT06792253 · CT.gov ↗
What to watch
Phase 4Lupus NephritisRecruiting
Est. primary completion 2028-12-31 · NCT05207358 · CT.gov ↗
What to watch
Early phase / not applicableLupus NephritisNot yet recruiting
Est. primary completion 2028-12-31 · NCT07675291 · CT.gov ↗
What to watch
Early phase / not applicableEBV Infection After Allogenic HSCTRecruiting
Est. primary completion 2028-12-31 · NCT07693881 · CT.gov ↗
What to watch
2029 (33)
January 2029 (2)
Phase 1Renal FailureActive not recruiting
Est. primary completion 2029-01 · NCT04540380 · CT.gov ↗
What to watch
Phase 1B-cell Non Hodgkin LymphomaRecruiting
Est. primary completion 2029-01 · NCT07691606 · CT.gov ↗
What to watch
February 2029 (1)
Phase 4Primary Immune Thrombocytopenia (ITP)Recruiting
Est. primary completion 2029-02-10 · NCT04518475 · CT.gov ↗
What to watch
March 2029 (2)
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-03 · NCT06350318 · CT.gov ↗
What to watch
Phase 2B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Lymphoblastic LymphomaRecruiting
Est. primary completion 2029-03-30 · NCT06918431 · CT.gov ↗
What to watch
April 2029 (4)
Phase 1Large B-cell Lymphoma, Central Nervous System LymphomaNot yet recruiting
Est. primary completion 2029-04 · NCT07608731 · CT.gov ↗
What to watch
Phase 3Primary Mediastinal LymphomaActive not recruiting
Est. primary completion 2029-04-01 · NCT06188676 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-04-22 · NCT05952024 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaActive not recruiting
Est. primary completion 2029-04-26 · NCT05406401 · CT.gov ↗
What to watch
May 2029 (2)
Phase 1/2Follicular LymphomaActive not recruiting
Est. primary completion 2029-05-30 · NCT04669171 · CT.gov ↗
What to watch
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-05-31 · NCT07594899 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Large B-Cell Lymphoma (LBCL)Not yet recruiting
Est. primary completion 2029-06-30 · NCT07717177 · CT.gov ↗
What to watch
July 2029 (5)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-07-01 · NCT06364423 · CT.gov ↗
What to watch
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-07-02 · NCT06717347 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2029-07-08 · NCT06792825 · CT.gov ↗
What to watch
Phase 1AML/MDS, B-ALL, T-ALL, BPDCNRecruiting
Est. primary completion 2029-07-29 · NCT04318678 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2029-07-31 · NCT07643038 · CT.gov ↗
What to watch
August 2029 (2)
Phase 2Waldenstrom MacroglobulinemiaNot yet recruiting
Est. primary completion 2029-08-01 · NCT07464210 · CT.gov ↗
What to watch
Phase 4Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-08-15 · NCT07908888 · CT.gov ↗
What to watch
September 2029 (1)
Phase 3Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2029-09-30 · NCT06943872 · CT.gov ↗
What to watch
October 2029 (3)
Phase 2Mantle Cell Lymphoma (MCL)Not yet recruiting
Est. primary completion 2029-10-10 · NCT07855016 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-10-15 · NCT07365306 · CT.gov ↗
What to watch
Early phase / not applicableMembranous Nephropathy, Membranous Nephropathy - PLA2R Induced, Nephrotic SyndromeNot yet recruiting
Est. primary completion 2029-10-31 · NCT07811557 · CT.gov ↗
What to watch
November 2029 (3)
Phase 1Central Nervous System LymphomaRecruiting
Est. primary completion 2029-11 · NCT06607549 · CT.gov ↗
What to watch
Phase 2Mantle Cell Lymphoma, LymphomaRecruiting
Est. primary completion 2029-11-01 · NCT06854003 · CT.gov ↗
What to watch
Phase 1/2Mature B-Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2029-11-30 · NCT05533775 · CT.gov ↗
What to watch
December 2029 (7)
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-12 · NCT06664411 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2029-12 · NCT05409066 · CT.gov ↗
What to watch
Phase 4Epstein-Barr Virus InfectionsRecruiting
Est. primary completion 2029-12-01 · NCT04989491 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2029-12-30 · NCT07493148 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaNot yet recruiting
Est. primary completion 2029-12-31 · NCT06890585 · CT.gov ↗
What to watch
Phase 2Mantle Cell LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT05245656 · CT.gov ↗
What to watch
Early phase / not applicablePrimary Ocular Adnexal MALT LymphomaRecruiting
Est. primary completion 2029-12-31 · NCT06190301 · CT.gov ↗
What to watch
2030 (24)
January 2030 (2)
Phase 1/2Lysosomal Diseases, Gangliosidosis, GM1Recruiting
Est. primary completion 2030-01-01 · NCT03952637 · CT.gov ↗
What to watch
Phase 2Primary Angiitis of the Central Nervous System (PACNS) in RemissionNot yet recruiting
Est. primary completion 2030-01-01 · NCT07902492 · CT.gov ↗
What to watch
February 2030 (1)
Phase 4ANCA Associated Vasculitis (AAV), Polyangiitis (GPA), Microscopic Polyangiitis (MPA)Not yet recruiting
Est. primary completion 2030-02 · NCT07451847 · CT.gov ↗
What to watch
March 2030 (4)
Phase 2B Lymphoblastic LeukemiaRecruiting
Est. primary completion 2030-03 · NCT06336395 · CT.gov ↗
What to watch
Phase 2/3Waldenstrom MacroglobulinemiaRecruiting
Est. primary completion 2030-03 · NCT04061512 · CT.gov ↗
What to watch
Phase 1/2Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell LeukemiaRecruiting
Est. primary completion 2030-03-01 · NCT06965114 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2030-03-01 · NCT06563596 · CT.gov ↗
What to watch
April 2030 (3)
Phase 2Diffuse Large B Cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2030-04 · NCT06835530 · CT.gov ↗
What to watch
Phase 1/2Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell LymphomaRecruiting
Est. primary completion 2030-04-21 · NCT07578077 · CT.gov ↗
What to watch
Phase 1CNS LymphomaRecruiting
Est. primary completion 2030-04-30 · NCT06730542 · CT.gov ↗
What to watch
May 2030 (4)
Phase 2Systemic Sclerosis in AdultsNot yet recruiting
Est. primary completion 2030-05 · NCT07827742 · CT.gov ↗
What to watch
Phase 1/2Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell Non-Hodgkin LymphomaRecruiting
Est. primary completion 2030-05-20 · NCT06564038 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2030-05-31 · NCT07097363 · CT.gov ↗
What to watch
Phase 3Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications …Recruiting
Est. primary completion 2030-05-31 · NCT03394365 · CT.gov ↗
What to watch
June 2030 (1)
Phase 1/2Post-transplant Lymphoproliferative DisorderRecruiting
Est. primary completion 2030-06 · NCT07573436 · CT.gov ↗
What to watch
July 2030 (2)
Phase 2Marginal Zone Lymphoma(MZL)Not yet recruiting
Est. primary completion 2030-07 · NCT07654465 · CT.gov ↗
What to watch
Phase 2Hematological MalignanciesNot yet recruiting
Est. primary completion 2030-07-31 · NCT07137481 · CT.gov ↗
What to watch
September 2030 (3)
Phase 3Large B-cell LymphomaNot yet recruiting
Est. primary completion 2030-09-02 · NCT07911553 · CT.gov ↗
What to watch
Phase 2Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal Zone Lymphoma …Recruiting
Est. primary completion 2030-09-25 · NCT07583810 · CT.gov ↗
What to watch
Phase 2Idiopathic Pulmonary FibrosisNot yet recruiting
Est. primary completion 2030-09-30 · NCT07674745 · CT.gov ↗
What to watch
October 2030 (2)
Phase 1Follicular LymphomaNot yet recruiting
Est. primary completion 2030-10-08 · NCT07714421 · CT.gov ↗
What to watch
Phase 2Follicular LymphomaRecruiting
Est. primary completion 2030-10-31 · NCT07731789 · CT.gov ↗
What to watch
December 2030 (2)
Phase 1Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney TransplantationActive not recruiting
Est. primary completion 2030-12-31 · NCT06972069 · CT.gov ↗
What to watch
Phase 2Richter SyndromeNot yet recruiting
Est. primary completion 2030-12-31 · NCT07831395 · CT.gov ↗
What to watch
2031 (11)
February 2031 (3)
Phase 1/2Non Hodgkin Lymphoma, Solid TumorRecruiting
Est. primary completion 2031-02 · NCT07222631 · CT.gov ↗
What to watch
Phase 1Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2031-02-10 · NCT05091424 · CT.gov ↗
What to watch
Phase 2Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2031-02-22 · NCT03418038 · CT.gov ↗
What to watch
April 2031 (1)
Early phase / not applicableMarginal Zone Lymphoma(MZL)Not yet recruiting
Est. primary completion 2031-04-30 · NCT07299331 · CT.gov ↗
What to watch
May 2031 (2)
Phase 2/3B-cell Non Hodgkin LymphomaRecruiting
Est. primary completion 2031-05-01 · NCT05991388 · CT.gov ↗
What to watch
Phase 2Adult Burkitt LymphomaRecruiting
Est. primary completion 2031-05-30 · NCT07662928 · CT.gov ↗
What to watch
June 2031 (1)
Phase 3Mantle Cell LymphomaRecruiting
Est. primary completion 2031-06-25 · NCT06363994 · CT.gov ↗
What to watch
August 2031 (1)
Phase 3Membranous NephropathyRecruiting
Est. primary completion 2031-08-31 · NCT06341205 · CT.gov ↗
What to watch
December 2031 (3)
Phase 1/2Kidney Failure, Kidney Transplant; Complications, ChimeraRecruiting
Est. primary completion 2031-12 · NCT05900401 · CT.gov ↗
What to watch
Phase 2Marginal Zone LymphomaRecruiting
Est. primary completion 2031-12 · NCT06390956 · CT.gov ↗
What to watch
Phase 3Autoimmune Prematur Ovarian InsuffienceRecruiting
Est. primary completion 2031-12-31 · NCT07509840 · CT.gov ↗
What to watch
2032 (9)
January 2032 (1)
Phase 1Relapsed or Refractory B-cell Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-01 · NCT06824701 · CT.gov ↗
What to watch
March 2032 (2)
Phase 1/2Leukemia, LymphomaRecruiting
Est. primary completion 2032-03 · NCT07294677 · CT.gov ↗
What to watch
Phase 3Follicular LymphomaRecruiting
Est. primary completion 2032-03-31 · NCT06337318 · CT.gov ↗
What to watch
May 2032 (1)
Phase 4Pemphigus, Dermatologic DiseaseRecruiting
Est. primary completion 2032-05-01 · NCT05898308 · CT.gov ↗
What to watch
July 2032 (1)
Phase 2/3Follicular LymphomaRecruiting
Est. primary completion 2032-07-23 · NCT07634471 · CT.gov ↗
What to watch
October 2032 (1)
Phase 1/2SIOD, Cystinosis, FSGS, SLE Nephritis, CKD Stage 4Recruiting
Est. primary completion 2032-10 · NCT05508009 · CT.gov ↗
What to watch
November 2032 (1)
Phase 2Non-Hodgkin LymphomaActive not recruiting
Est. primary completion 2032-11 · NCT05283720 · CT.gov ↗
What to watch
December 2032 (2)
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2032-12 · NCT07285590 · CT.gov ↗
What to watch
Phase 2Presymptomatic Diabetes Type 1 (Stage 1), Diabetes Mellitus, Type I, Diabetes Mellitus, Type 1Recruiting
Est. primary completion 2032-12 · NCT06688331 · CT.gov ↗
What to watch
2033 (3)
February 2033 (1)
Phase 2Mantle Cell Lymphoma (MCL)Recruiting
Est. primary completion 2033-02-10 · NCT06846489 · CT.gov ↗
What to watch
May 2033 (1)
Phase 1/2Chronic Lymphocytic LeukemiaRecruiting
Est. primary completion 2033-05 · NCT07520006 · CT.gov ↗
What to watch
November 2033 (1)
Phase 2/3Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements, Refractory Burkitt Lymphoma …Recruiting
Est. primary completion 2033-11-01 · NCT07724457 · CT.gov ↗
What to watch
2035 (2)
May 2035 (1)
Phase 2Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal HemoglobinuriaRecruiting
Est. primary completion 2035-05-01 · NCT06412497 · CT.gov ↗
What to watch
October 2035 (1)
Phase 3Diffuse Large B-Cell LymphomaRecruiting
Est. primary completion 2035-10-01 · NCT07220187 · CT.gov ↗
What to watch
2037 (2)
July 2037 (1)
Phase 1/2Crohn DiseaseNot yet recruiting
Est. primary completion 2037-07 · NCT06986382 · CT.gov ↗
What to watch
November 2037 (1)
Phase 3Follicular LymphomaActive not recruiting
Est. primary completion 2037-11 · NCT06191744 · CT.gov ↗
What to watch
2038 (1)
August 2038 (1)
Phase 3Mantle Cell LymphomaRecruiting
Est. primary completion 2038-08-31 · NCT05976763 · CT.gov ↗
What to watch
2042 (1)
July 2042 (1)
Phase 1GlioblastomaActive not recruiting
Est. primary completion 2042-07 · NCT06973096 · CT.gov ↗
What to watch

See the full readout calendar ↗